{
    "title": "Blood biomarkers for the non\u2010invasive diagnosis of endometriosis",
    "abstract": "Background About 10% of reproductive\u2010aged women suffer from endometriosis, a costly chronic disease causing pelvic pain and subfertility. Laparoscopy is the gold standard diagnostic test for endometriosis, but is expensive and carries surgical risks. Currently, there are no non\u2010invasive or minimally invasive tests available in clinical practice to accurately diagnose endometriosis. Although other reviews have assessed the ability of blood tests to diagnose endometriosis, this is the first review to use Cochrane methods, providing an update on the rapidly expanding literature in this field.    Objectives To evaluate blood biomarkers as replacement tests for diagnostic surgery and as triage tests to inform decisions on surgery for endometriosis. Specific objectives include:  1. To provide summary estimates of the diagnostic accuracy of blood biomarkers for the diagnosis of peritoneal, ovarian and deep infiltrating pelvic endometriosis, compared to surgical diagnosis as a reference standard.  2. To assess the diagnostic utility of biomarkers that could differentiate ovarian endometrioma from other ovarian masses.    Search methods We did not restrict the searches to particular study designs, language or publication dates. We searched CENTRAL to July 2015, MEDLINE and EMBASE to May 2015, as well as these databases to 20 April 2015: CINAHL, PsycINFO, Web of Science, LILACS, OAIster, TRIP, ClinicalTrials.gov, DARE and PubMed.    Selection criteria We considered published, peer\u2010reviewed, randomised controlled or cross\u2010sectional studies of any size, including prospectively collected samples from any population of reproductive\u2010aged women suspected of having one or more of the following target conditions: ovarian, peritoneal or deep infiltrating endometriosis (DIE). We included studies comparing the diagnostic test accuracy of one or more blood biomarkers with the findings of surgical visualisation of endometriotic lesions.    Data collection and analysis Two authors independently collected and performed a quality assessment of data from each study. For each diagnostic test, we classified the data as positive or negative for the surgical detection of endometriosis, and we calculated sensitivity and specificity estimates. We used the bivariate model to obtain pooled estimates of sensitivity and specificity whenever sufficient datasets were available. The predetermined criteria for a clinically useful blood test to replace diagnostic surgery were a sensitivity of 0.94 and a specificity of 0.79 to detect endometriosis. We set the criteria for triage tests at a sensitivity of \u2265 0.95 and a specificity of \u2265 0.50, which 'rules out' the diagnosis with high accuracy if there is a negative test result (SnOUT test), or a sensitivity of \u2265 0.50 and a specificity of \u2265 0.95, which 'rules in' the diagnosis with high accuracy if there is a positive result (SpIN test).    Main results We included 141 studies that involved 15,141 participants and evaluated 122 blood biomarkers. All the studies were of poor methodological quality. Studies evaluated the blood biomarkers either in a specific phase of the menstrual cycle or irrespective of the cycle phase, and they tested for them in serum, plasma or whole blood. Included women were a selected population with a high frequency of endometriosis (10% to 85%), in which surgery was indicated for endometriosis, infertility work\u2010up or ovarian mass. Seventy studies evaluated the diagnostic performance of 47 blood biomarkers for endometriosis (44 single\u2010marker tests and 30 combined tests of two to six blood biomarkers). These were angiogenesis/growth factors, apoptosis markers, cell adhesion molecules, high\u2010throughput markers, hormonal markers, immune system/inflammatory markers, oxidative stress markers, microRNAs, tumour markers and other proteins. Most of these biomarkers were assessed in small individual studies, often using different cut\u2010off thresholds, and we could only perform meta\u2010analyses on the data sets for anti\u2010endometrial antibodies, interleukin\u20106 (IL\u20106), cancer antigen\u201019.9 (CA\u201019.9) and CA\u2010125. Diagnostic estimates varied significantly between studies for each of these biomarkers, and CA\u2010125 was the only marker with sufficient data to reliably assess sources of heterogeneity.  The mean sensitivities and specificities of anti\u2010endometrial antibodies (4 studies, 759 women) were 0.81 (95% confidence interval (CI) 0.76 to 0.87) and 0.75 (95% CI 0.46 to 1.00). For IL\u20106, with a cut\u2010off value of > 1.90 to 2.00 pg/ml (3 studies, 309 women), sensitivity was 0.63 (95% CI 0.52 to 0.75) and specificity was 0.69 (95% CI 0.57 to 0.82). For CA\u201019.9, with a cut\u2010off value of > 37.0 IU/ml (3 studies, 330 women), sensitivity was 0.36 (95% CI 0.26 to 0.45) and specificity was 0.87 (95% CI 0.75 to 0.99).  Studies assessed CA\u2010125 at different thresholds, demonstrating the following mean sensitivities and specificities: for cut\u2010off > 10.0 to 14.7 U/ml: 0.70 (95% CI 0.63 to 0.77) and 0.64 (95% CI 0.47 to 0.82); for cut\u2010off > 16.0 to 17.6 U/ml: 0.56 (95% CI 0.24, 0.88) and 0.91 (95% CI 0.75, 1.00); for cut\u2010off > 20.0 U/ml: 0.67 (95% CI 0.50 to 0.85) and 0.69 (95% CI 0.58 to 0.80); for cut\u2010off > 25.0 to 26.0 U/ml: 0.73 (95% CI 0.67 to 0.79) and 0.70 (95% CI 0.63 to 0.77); for cut\u2010off > 30.0 to 33.0 U/ml: 0.62 (95% CI 0.45 to 0.79) and 0.76 (95% CI 0.53 to 1.00); and for cut\u2010off > 35.0 to 36.0 U/ml: 0.40 (95% CI 0.32 to 0.49) and 0.91 (95% CI 0.88 to 0.94).  We could not statistically evaluate other biomarkers meaningfully, including biomarkers that were assessed for their ability to differentiate endometrioma from other benign ovarian cysts.  Eighty\u2010two studies evaluated 97 biomarkers that did not differentiate women with endometriosis from disease\u2010free controls. Of these, 22 biomarkers demonstrated conflicting results, with some studies showing differential expression and others no evidence of a difference between the endometriosis and control groups.    Authors' conclusions Of the biomarkers that were subjected to meta\u2010analysis, none consistently met the criteria for a replacement or triage diagnostic test. A subset of blood biomarkers could prove useful either for detecting pelvic endometriosis or for differentiating ovarian endometrioma from other benign ovarian masses, but there was insufficient evidence to draw meaningful conclusions. Overall, none of the biomarkers displayed enough accuracy to be used clinically outside a research setting. We also identified blood biomarkers that demonstrated no diagnostic value in endometriosis and recommend focusing research resources on evaluating other more clinically useful biomarkers.",
    "review_type": "Diagnostic",
    "doi": "https://doi.org/10.1002/14651858.CD012179",
    "review_id": "CD012179",
    "criteria": {
        "Types of studies": "Published peer\u2010reviewed studies that compared the results of one or several types of blood biomarker tests with the results obtained from a surgical diagnosis of endometriosis. We included the following types of studies. Randomised controlled trials (RCTs).   Observational studies with the following designs.   Single\u2010gate design (studies with a single set of inclusion criteria defined by clinical presentation). All participants had clinically suspected endometriosis.    Two\u2010gate design (studies where participants are sampled from distinct populations with respect to clinical presentation). The same study includes participants with a clinical suspicion of having the target condition (e.g. women with pelvic pain) and also participants in whom the target condition is not suspected (e.g. women admitted for tubal ligation). Two\u2010gate studies were eligible only where all cases and controls belonged to the same population with respect to the reference standard (i.e. all the participants were scheduled for laparoscopy) (Rutjes 2005).      Studies performed on prospectively collected samples, irrespective of the actual time of the test assay. The timing of sample collection relative to surgery is important because the surgical excision of endometriotic lesions could influence blood biomarker expression and hence bias the results. Therefore, we only included studies that drew blood before the surgical procedure, i.e. 'prospectively collected'. We considered to be eligible the studies performed on tissue bank samples collected from prospectively recruited, well\u2010defined populations, which prevented the omission of valuable data from adequately designed studies. The time interval between sample collection and laboratory testing may influence test outcomes, which could be dependent on sample storage conditions and the stability of each individual biomarker during storage and freeze\u2010thawing. This information was not readily available for most molecules, and we did not address it in this review, but we will consider it in future updates if more evidence emerges. Randomised controlled trials (RCTs). Observational studies with the following designs. Single\u2010gate design (studies with a single set of inclusion criteria defined by clinical presentation). All participants had clinically suspected endometriosis. Two\u2010gate design (studies where participants are sampled from distinct populations with respect to clinical presentation). The same study includes participants with a clinical suspicion of having the target condition (e.g. women with pelvic pain) and also participants in whom the target condition is not suspected (e.g. women admitted for tubal ligation). Two\u2010gate studies were eligible only where all cases and controls belonged to the same population with respect to the reference standard (i.e. all the participants were scheduled for laparoscopy) (Rutjes 2005). Studies performed on prospectively collected samples, irrespective of the actual time of the test assay. The timing of sample collection relative to surgery is important because the surgical excision of endometriotic lesions could influence blood biomarker expression and hence bias the results. Therefore, we only included studies that drew blood before the surgical procedure, i.e. 'prospectively collected'. We considered to be eligible the studies performed on tissue bank samples collected from prospectively recruited, well\u2010defined populations, which prevented the omission of valuable data from adequately designed studies. The time interval between sample collection and laboratory testing may influence test outcomes, which could be dependent on sample storage conditions and the stability of each individual biomarker during storage and freeze\u2010thawing. This information was not readily available for most molecules, and we did not address it in this review, but we will consider it in future updates if more evidence emerges. We did not impose limits on eligibility related to the healthcare settings where the study took place, the language of publication, the number of participants in the included studies or the number of studies that evaluated each index test. We excluded the following types of studies. Narrative or systematic reviews.   Studies of retrospective design where investigators collected samples after execution of the reference test.    Studies of retrospective design where investigators selected participants from retrospective review of the case notes/archived samples and where information on recruitment methods or study population was not available.    Case reports or case series.   Studies reported only in abstract form or in conference proceedings where the full text was not available. We applied this limitation after facing substantial difficulty in obtaining the information from the abstracts, which precluded a reliable assessment of eligibility and methodological quality. Narrative or systematic reviews. Studies of retrospective design where investigators collected samples after execution of the reference test. Studies of retrospective design where investigators selected participants from retrospective review of the case notes/archived samples and where information on recruitment methods or study population was not available. Case reports or case series. Studies reported only in abstract form or in conference proceedings where the full text was not available. We applied this limitation after facing substantial difficulty in obtaining the information from the abstracts, which precluded a reliable assessment of eligibility and methodological quality.",
        "Participants": "Study participants included reproductive\u2010aged women (puberty to menopause) with suspected endometriosis based on clinical symptoms, pelvic examination or both, who undertook the index test as well as the reference standard. Participants came from populations of women undergoing abdominal surgery for the following indications. Clinically suspected endometriosis (pelvic pain, infertility, abnormal pelvic examination, or a combination of the above).    Ovarian mass, regardless of symptoms.   A mixed group consisting of women with suspected endometriosis/ovarian mass or women with other benign gynaecological conditions (e.g. surgical sterilisation, fibroid uterus, etc).    Asymptomatic women who have an incidental finding of endometriosis at surgery performed for another indication. Clinically suspected endometriosis (pelvic pain, infertility, abnormal pelvic examination, or a combination of the above). Ovarian mass, regardless of symptoms. A mixed group consisting of women with suspected endometriosis/ovarian mass or women with other benign gynaecological conditions (e.g. surgical sterilisation, fibroid uterus, etc). Asymptomatic women who have an incidental finding of endometriosis at surgery performed for another indication. Studies that included participants of postmenopausal age were eligible when the data for the reproductive age group was available in isolation. We excluded studies with participants that clearly would not undergo the index test in the relevant clinical situation or would not benefit from the test (e.g. women with ectopic pregnancies or acute pelvic inflammatory disease). We also excluded publications that only analysed participants with a positive index test or reference standard and did not provide data for the whole cohort.",
        "Index tests": "We assessed any type of blood\u2010based biomarker for endometriosis either separately or in combination with other blood tests. We included index tests performed on whole blood, plasma or serum. We present the assessed index tests in Table 2 (classified by biological subgroups) and in Appendix 1 (alphabetical order with annotation for biological subgroups). We included the tests performed in one or several phases of menstrual cycle. The combined evaluations of blood biomarkers with other methods for diagnosing endometriosis (e.g. pelvic examination, imaging, urine or endometrial tests) are beyond the scope of this review and are presented separately in another review, 'Combined tests for the non\u2010invasive diagnosis of endometriosis'. We excluded studies that solely assessed specific technical aspects, presented qualitative descriptions of lesion appearance or reported interobserver variability of the index tests, without reporting the data on diagnostic performance. When the evaluated biomarker(s) showed differential expression between the groups of women with and without endometriosis, we only considered the study if it reported data with sufficient detail for the construction of 2 x 2 contingency tables. However, when the contingency tables were not available because the expression level of index test did not significantly differ between the groups and the inclusion criteria were otherwise met, we made a critical appraisal and presented the study in the descriptive part of the review. Thus, we evaluated the adequately designed studies that identified biomarkers without diagnostic value, as they provide information that is likely to focus future research on other more clinically useful biomarkers.This methodology also identified biomarkers that were associated with endometriosis in some but not other studies. We did not include evaluations of screening or predictive accuracy tests in this review. We considered the diagnostic performance of an index test to be high when the test reached the criteria for a replacement test (sensitivity of equal or greater than 0.94 with specificity of equal or greater than 0.79) or triage test (sensitivity of equal or greater than 0.95 with specificity of equal or greater than 0.50 or vice versa) or approached these criteria (diagnostic estimates within 0.05 of the set thresholds). We considered all other diagnostic estimates to be low.",
        "Target conditions": "Pelvic endometriosis, defined as endometrial tissue located in the pelvic cavity: involving any of the following: pelvic organs, peritoneum and pouch of Douglas. We assessed three types of pelvic endometriosis. Peritoneal endometriosis, defined as endometrial deposits detected on peritoneum covering pelvic organs, pelvic side walls or pouch of Douglas.    Ovarian endometriosis (endometrioma), defined as an ovarian cyst lined by endometrial tissue, appearing as an ovarian mass of varying size.    Deep infiltrating endometriosis (DIE), defined as subperitoneal infiltration of endometrial implants, i.e. when the endometriotic implants penetrate the retroperitoneal space at a distance of 5 mm or more (Koninckx 1991). DIE may be present in multiple locations, involving either the anterior or posterior pelvic compartments, or both. Peritoneal endometriosis, defined as endometrial deposits detected on peritoneum covering pelvic organs, pelvic side walls or pouch of Douglas. Ovarian endometriosis (endometrioma), defined as an ovarian cyst lined by endometrial tissue, appearing as an ovarian mass of varying size. Deep infiltrating endometriosis (DIE), defined as subperitoneal infiltration of endometrial implants, i.e. when the endometriotic implants penetrate the retroperitoneal space at a distance of 5 mm or more (Koninckx 1991). DIE may be present in multiple locations, involving either the anterior or posterior pelvic compartments, or both. We did not include certain rare types of endometriosis such as extrapelvic, bladder and ureteric endometriosis because the majority were reported in case reports or case series, and laparoscopy or laparotomy are not reliable reference standards for these conditions. We excluded the studies where diagnosis of endometriosis was not the primary outcome (e.g. malignant versus benign masses or normal versus abnormal pelvis) and separate data for endometriosis was not available. We also excluded the studies where the findings of the index test formed the basis of selection for the reference standard, because this was likely to distort an assessment of the diagnostic value of the index test. We did include studies that recruited selected populations of women with endometriosis (i.e. those with specific rASRM stages), because there is a poor correlation between the rASRM classification and infertility or pain symptoms. Exclusion of these studies could result in the loss of potentially important diagnostic information from otherwise eligible publications. Where possible, we addressed the impact of these studies in the assessment of heterogeneity. When a study analysed a large population with a wide spectrum of endometriosis and additionally reported a subgroup analysis of the different stages of disease severity, we only considered estimates for the entire population. This is because a subgroup analysis would not directly address the review question regarding the clinical utility of the biomarker in disease detection.",
        "Reference standards": "The reference standard was visualisation of endometriosis at surgery (laparoscopy or laparotomy) with or without histological confirmation, as this is currently the best available test for endometriosis. If reported, we reviewed information regarding the inter\u2010 and intraobserver correlation of the reference standard. We only included studies in which the reference test was performed within 12 months of the blood sample collection, on the assumption that disease status could change within a period of one year or longer, either naturally or as a result of treatment. We excluded studies in which the participants did not undergo the reference standard or where the findings of the index test formed the basis of selection for undertaking the reference standard, as this was likely to distort an assessment of the diagnostic value of the index test. Types of studies   Published and peer\u2010reviewed   RCTs   Observational designs, including:   single\u2010gate design (single set of inclusion criteria defined by clinical presentation): all the participants had clinically suspected endometriosis;    two\u2010gate design (two sets of inclusion criteria with respect to clinical presentation and one set of inclusion criteria with respect to reference standard): the participants with or without a clinical suspicion of endometriosis scheduled for abdominal surgery.      Published in any language   Performed in any healthcare setting   Any sample size     Participants   Reproductive\u2010aged women   Clinically suspected endometriosis, including:   women who underwent abdominal surgery for other benign gynaecological conditions and had a surgical assessment for presence/absence of endometriosis;    asymptomatic women who have an incidental finding of endometriosis at surgery performed for another indication.      Undertook both the index test and reference standard     Index tests   One or several types of blood biomarkers   Data reported in sufficient detail for the construction of 2 x 2 tables for the tests that showed differential expression between the groups    Biomarkers where a 2 x 2 tables could not be constructed because the results did not differ between women with and without endometriosis, but all other inclusion criteria were met.      Target condition   Pelvic endometriosis   Peritoneal endometriosis   Ovarian endometrioma   DIE   Combinations of the above       Reference standard   Surgical visualisation of lesions for the diagnosis of endometriosis (laparoscopy or laparotomy) with or without histological verification    Performed within 12 months of the endometrial sample collection Types of studies Published and peer\u2010reviewed RCTs Observational designs, including: single\u2010gate design (single set of inclusion criteria defined by clinical presentation): all the participants had clinically suspected endometriosis; two\u2010gate design (two sets of inclusion criteria with respect to clinical presentation and one set of inclusion criteria with respect to reference standard): the participants with or without a clinical suspicion of endometriosis scheduled for abdominal surgery. Published in any language Performed in any healthcare setting Any sample size Participants Reproductive\u2010aged women Clinically suspected endometriosis, including: women who underwent abdominal surgery for other benign gynaecological conditions and had a surgical assessment for presence/absence of endometriosis; asymptomatic women who have an incidental finding of endometriosis at surgery performed for another indication. Undertook both the index test and reference standard Index tests One or several types of blood biomarkers Data reported in sufficient detail for the construction of 2 x 2 tables for the tests that showed differential expression between the groups Biomarkers where a 2 x 2 tables could not be constructed because the results did not differ between women with and without endometriosis, but all other inclusion criteria were met. Target condition Pelvic endometriosis Peritoneal endometriosis Ovarian endometrioma DIE Combinations of the above Reference standard Surgical visualisation of lesions for the diagnosis of endometriosis (laparoscopy or laparotomy) with or without histological verification Performed within 12 months of the endometrial sample collection Types of studies   Narrative or systematic reviews   Retrospective design where the execution of reference test preceded the collection of the blood sample    Prospectively collected samples that were selected from the archived material, but where information on the study population or the selection process was unclear    Case reports or case series   Conference proceedings     Participants   Included cohort was not representative of the target population that would benefit from the test (e.g. women with known genital tract malignancy, ectopic pregnancies or acute pelvic inflammatory disease)    Study included participants of postmenopausal age, and the data for the reproductive age group were not available in isolation    Analysis only included participants with positive index test or positive reference standard      Index tests   Blood biomarkers presented in combination with other diagnostic tests for endometriosis, and separate information for blood biomarkers was not available    Study presented only specific technical aspects of an index test or focused on the biological events, rather than diagnostic performance of the test    Study assessed screening or predictive test accuracy     Target condition   Endometriosis was not the primary outcome of the trial (e.g. malignant versus benign masses or normal versus abnormal pelvis)    Atypical, rare sites of endometriosis     Reference standard   Reference standard performed only in a subset of study/control group   Findings of the index test formed the basis of selection for the reference standard   Other than specified in inclusion criteria Types of studies Narrative or systematic reviews Retrospective design where the execution of reference test preceded the collection of the blood sample Prospectively collected samples that were selected from the archived material, but where information on the study population or the selection process was unclear Case reports or case series Conference proceedings Participants Included cohort was not representative of the target population that would benefit from the test (e.g. women with known genital tract malignancy, ectopic pregnancies or acute pelvic inflammatory disease) Study included participants of postmenopausal age, and the data for the reproductive age group were not available in isolation Analysis only included participants with positive index test or positive reference standard Index tests Blood biomarkers presented in combination with other diagnostic tests for endometriosis, and separate information for blood biomarkers was not available Study presented only specific technical aspects of an index test or focused on the biological events, rather than diagnostic performance of the test Study assessed screening or predictive test accuracy Target condition Endometriosis was not the primary outcome of the trial (e.g. malignant versus benign masses or normal versus abnormal pelvis) Atypical, rare sites of endometriosis Reference standard Reference standard performed only in a subset of study/control group Findings of the index test formed the basis of selection for the reference standard Other than specified in inclusion criteria",
        "Summary of inclusion and exclusion criteria": "Inclusion criteria    Types of studies   Published and peer\u2010reviewed   RCTs   Observational designs, including:   single\u2010gate design (single set of inclusion criteria defined by clinical presentation): all the participants had clinically suspected endometriosis;    two\u2010gate design (two sets of inclusion criteria with respect to clinical presentation and one set of inclusion criteria with respect to reference standard): the participants with or without a clinical suspicion of endometriosis scheduled for abdominal surgery.      Published in any language   Performed in any healthcare setting   Any sample size     Participants   Reproductive\u2010aged women   Clinically suspected endometriosis, including:   women who underwent abdominal surgery for other benign gynaecological conditions and had a surgical assessment for presence/absence of endometriosis;    asymptomatic women who have an incidental finding of endometriosis at surgery performed for another indication.      Undertook both the index test and reference standard     Index tests   One or several types of blood biomarkers   Data reported in sufficient detail for the construction of 2 x 2 tables for the tests that showed differential expression between the groups    Biomarkers where a 2 x 2 tables could not be constructed because the results did not differ between women with and without endometriosis, but all other inclusion criteria were met.      Target condition   Pelvic endometriosis   Peritoneal endometriosis   Ovarian endometrioma   DIE   Combinations of the above       Reference standard   Surgical visualisation of lesions for the diagnosis of endometriosis (laparoscopy or laparotomy) with or without histological verification    Performed within 12 months of the endometrial sample collection        Exclusion criteria    Types of studies   Narrative or systematic reviews   Retrospective design where the execution of reference test preceded the collection of the blood sample    Prospectively collected samples that were selected from the archived material, but where information on the study population or the selection process was unclear    Case reports or case series   Conference proceedings     Participants   Included cohort was not representative of the target population that would benefit from the test (e.g. women with known genital tract malignancy, ectopic pregnancies or acute pelvic inflammatory disease)    Study included participants of postmenopausal age, and the data for the reproductive age group were not available in isolation    Analysis only included participants with positive index test or positive reference standard      Index tests   Blood biomarkers presented in combination with other diagnostic tests for endometriosis, and separate information for blood biomarkers was not available    Study presented only specific technical aspects of an index test or focused on the biological events, rather than diagnostic performance of the test    Study assessed screening or predictive test accuracy     Target condition   Endometriosis was not the primary outcome of the trial (e.g. malignant versus benign masses or normal versus abnormal pelvis)    Atypical, rare sites of endometriosis     Reference standard   Reference standard performed only in a subset of study/control group   Findings of the index test formed the basis of selection for the reference standard   Other than specified in inclusion criteria",
        "null": ""
    },
    "search_strategy": {
        "Appendix 1. Alphabetical list of blood biomarkers": "Biomarker    Biological group    Biological subgroup 1    Biological subgroup 2      1   Angiogenic activity of serum   Angiogenesis and growth factors and their receptors       2   Annexin V   Apoptosis markers       3   Anti\u2010endometrial Abs or AEA (anti\u2010endometrial autoantibodies)   Immune system and inflammatory markers   Autoantibodies      4   Anti\u2010laminin\u20101 Abs (anti\u2010laminin autoantibodies)   Immune system and inflammatory markers   Autoantibodies      5   Anti\u2010sperm Abs (anti\u2010sperm autoantibodies)   Immune system and inflammatory markers   Autoantibodies      6   Anti\u2010survivin Abs (anti\u2010survivin antibodies)   Apoptosis markers       7   Anti\u2010ZP Abs (anti\u2010zona pellucida autoantibodies)   Immune system and inflammatory markers   Autoantibodies      8   Apoptotic cells   Apoptosis markers       9   Ascorbic acid   Oxidative stress markers       10   Biglycan   Cell adhesion molecules and other matrix\u2010related proteins       11   B\u2010lymphocytes   Immune system and inflammatory markers   Immune cells   Peripheral blood mononuclear cells (PBMC)     12   C3a (anaphylatoxin)   Immune system and inflammatory markers   Other immune/inflammatory markers      13   CA\u2010125 (cancer antigen\u2010125)   Tumour markers       14   CA\u201015.3 (cancer antigen\u201015.3)   Tumour markers       15   CA\u201019.9 (cancer antigen\u201019.9)   Tumour markers       16   CA\u201072 (TAG\u201072) (cancer antigen\u201072 or (tumour associated glycoprotein\u201072))   Tumour markers       17   CAC (circulating angiogenic cells)   Angiogenesis and growth factors and their receptors       18   Carbonyls   Oxidative stress markers       19   CCR1 (C\u2010C motif receptor 1)   Immune system and inflammatory markers   Chemokines      20   c\u2010erbB\u20102 (HER\u20102/neu) (erythroblastosis oncogene B or human epidermal growth factor receptor\u20102 derived from glioblastoma)    Tumour markers       21   CK 19 (cytokeratin\u201019)   Cytoskeleton molecules       22   CNTF (ciliary neurotrophic factor)   Nerve growth markers       23   Copeptin   Immune system and inflammatory markers   Other immune/inflammatory markers      24   CRP (C\u2010reactive protein) or hs\u2010CRP (high sensitive C\u2010reactive protein)   Immune system and inflammatory markers   Other immune/inflammatory markers      25   DBP (vitamin D binding protein)   Other peptides/proteins shown to influence key events implicated in endometriosis       26   E2 (oestradiol)   Hormonal markers       27   EGF (epidermal growth factor)   Angiogenesis and growth factors and their receptors       28   Enolase   Other peptides/proteins shown to influence key events implicated in endometriosis       29   Epo (erythropoietin)   Immune system and inflammatory markers   Other cytokines      30   Follistatin   Other peptides/proteins shown to influence key events implicated in endometriosis       31   FSH (follicle stimulating hormone)   Hormonal markers       32   GDNF (glial\u2010derived neurotrophic factor)   Nerve growth markers       33   glycodelin\u2010A (PP14 or PAEP) (placental protein 14 or progestogen\u2010associated endometrial protein)    Angiogenesis and growth factors and their receptors       34   GM\u2010CSF (granulocyte macrophage\u2010colony stimulating factor) or sGM\u2010CSF (soluble granulocyte macrophage\u2010colony stimulating factor)    Immune system and inflammatory markers   Other cytokines      35   GSH (glutathione)   Oxidative stress markers       36   Haemoglobin   Immune system and inflammatory markers   Immune cells   Other blood cells and blood cell parameters     37   HE4 (human epididymal secretory protein E4)   Tumour markers       38   HGF (hepatocyte growth factor)   Angiogenesis and growth factors and their receptors       39   HSP70 (heat shock protein 70)   Oxidative stress markers       40   IFN\u2010\u03b3 (interferon\u2010gamma) or sIFN\u2010\u03b3 (soluble interferon\u2010gamma)   Immune system and inflammatory markers   Other cytokines      41   IGF\u20101 (insulin\u2010like growth factor\u20101) or sIGF\u20101 (soluble Insulin\u2010like growth factor\u20101)   Angiogenesis and growth factors and their receptors       42   IGF\u20102 (insulin\u2010like growth factor\u20102)   Angiogenesis and growth factors and their receptors       43   IGFBP\u20103 (insulin\u2010like growth factor binding protein\u20103)   Angiogenesis and growth factors and their receptors       44   IL\u20101\u03b2   Immune system and inflammatory markers   Interleukins      45   IL\u20102   Immune system and inflammatory markers   Interleukins      46   IL\u20104   Immune system and inflammatory markers   Interleukins      47   IL\u20106   Immune system and inflammatory markers   Interleukins      48   IL\u20108   Immune system and inflammatory markers   Interleukins      49   IL\u201010   Immune system and inflammatory markers   Interleukins      50   IL\u201012   Immune system and inflammatory markers   Interleukins      51   IL\u201013   Immune system and inflammatory markers   Interleukins      52   IL\u201015   Immune system and inflammatory markers   Interleukins      53   IL\u201016   Immune system and inflammatory markers   Interleukins      54   IL\u201017   Immune system and inflammatory markers   Interleukins      55   IL\u201018   Immune system and inflammatory markers   Interleukins      56   IL\u201023   Immune system and inflammatory markers   Interleukins      57   IMA (ischemia\u2010modified albumin)   Oxidative stress markers       58   Immunoglobulins IgA or IgG   Immune system and inflammatory markers   Other immune/inflammatory markers      59   Leptin   Angiogenesis and growth factors and their receptors       60   LH (luteinizing hormone)   Hormonal markers       61   LN\u20101 (laminin\u20101)   Cell adhesion molecules and other matrix\u2010related proteins       62   Lymphocytes   Immune system and inflammatory markers   Immune cells   Peripheral blood mononuclear cells (PBMC)     63   Malondialdehyde   Oxidative stress markers       64   MCP\u20101 (monocyte chemotactic protein\u20101)   Immune system and inflammatory markers   Chemokines      65   Metabolome   High\u2010throughput molecular markers       66   MIF (macrophage migration inhibitory factor)   Immune system and inflammatory markers   Other cytokines      67   miR\u2010122   Post\u2010transcriptional regulators of gene expression (microRNAs)       68   miR\u2010141*   Post\u2010transcriptional regulators of gene expression (microRNAs)       69   miR\u2010145*   Post\u2010transcriptional regulators of gene expression (microRNAs)       70   miR\u201017\u20105   Post\u2010transcriptional regulators of gene expression (microRNAs)       71   miR\u2010199a   Post\u2010transcriptional regulators of gene expression (microRNAs)       72   miR\u201020a   Post\u2010transcriptional regulators of gene expression (microRNAs)       73   miR\u201022   Post\u2010transcriptional regulators of gene expression (microRNAs)       74   miR\u2010532\u20103p   Post\u2010transcriptional regulators of gene expression (microRNAs)       75   miR\u20109*   Post\u2010transcriptional regulators of gene expression (microRNAs)       76   MMP\u20109 (matrix metalloproteinase\u20109)   Cell adhesion molecules and other matrix\u2010related proteins       77   Monocytes/macrophages   Immune system and inflammatory markers   Immune cells   Peripheral blood mononuclear cells (PBMC)     78   MPO (myeloperoxidase)   Immune system and inflammatory markers   Other immune/inflammatory markers      79   MPV (mean platelet volume)   Immune system and inflammatory markers   Immune cells   Other blood cells and blood cell parameters     80   NAG (N\u2010acetyl\u2010b\u2010Dglucosaminidase)   Immune system and inflammatory markers   Other immune/inflammatory markers      81   Neutrophils   Immune system and inflammatory markers   Immune cells   Peripheral blood mononuclear cells (PBMC)     82   NGF (nerve growth factor)   Nerve growth markers       83   Nitrotyrosine   Oxidative stress markers       84   NK (natural killer cells)   Immune system and inflammatory markers   Immune cells   Peripheral blood mononuclear cells (PBMC)     85   NKR CD158b+ (KIR2DL2+NK) (killer cell inhibitory receptor subfamily 2DL2 on NK cells)   Immune system and inflammatory markers   Immune cells   Peripheral blood mononuclear cells (PBMC)     86   NKR CD94 + (lectin\u2010like receptor on natural killer cells)   Immune system and inflammatory markers   Immune cells   Peripheral blood mononuclear cells (PBMC)     87   NLR (neutrophil/lymphocyte ratio)   Immune system and inflammatory markers   Immune cells   Peripheral blood mononuclear cells (PBMC)     88   NT4 (neurotrophin 4)   Nerve growth markers       89   PAEP (glycodelin) (progestagen\u2010associated endometrial protein)   Angiogenesis and growth factors and their receptors       90   PDGF (platelet derived growth factor)   Angiogenesis and growth factors and their receptors       91   PDPK1 (phosphoinositide dependent protein kinase 1)   Other peptides/proteins shown to influence key events implicated in endometriosis       92   PGE2 (prostaglandin E2)   Immune system and inflammatory markers   Other immune/inflammatory markers      93   Phospholipid fatty acids   Immune system and inflammatory markers   Other immune/inflammatory markers      94   PLA2G2A (phospholipase A2 group IIA)   Immune system and inflammatory markers   Other immune/inflammatory markers      95   Platelet count   Immune system and inflammatory markers   Immune cells   Other blood cells and blood cell parameters     96   PLR (platelet/lymphocyte ratio)   Immune system and inflammatory markers   Immune cells   Other blood cells and blood cell parameters     97   PON\u20101 (paraoxonase\u20101)   Oxidative stress markers       98   Progesterone   Hormonal markers       99   Prolactin   Hormonal markers       100   Proteome   High\u2010throughput molecular markers       101   RANTES (regulated on activation, normal T cell expressed and secreted)   Immune system and inflammatory markers   Other immune/inflammatory markers      102   sCD163 (soluble haemoglobin scavenger receptor)   Immune system and inflammatory markers   Other immune/inflammatory markers      103   sCD23 (soluble CD23, low\u2010affinity IgE receptor)   Immune system and inflammatory markers   Other immune/inflammatory markers      104   sEGF\u2010R (soluble epidermal growth factor\u2010receptor)   Angiogenesis/ Growth factors and their receptors       105   sE\u2010selectin (soluble E selectin)   Cell adhesion molecules and other matrix\u2010related proteins       106   sFas (soluble Fas)   Apoptosis markers       107   sFlt\u20101 (sVEGFR\u20101) (soluble fms\u2010like tyrosine kinase or (variant of VEGF receptor 1)   Angiogenesis and growth factors and their receptors       108   sHLA\u2010I (soluble human leukocyte class I antigens)   Immune system and inflammatory markers   Other immune/inflammatory markers      109   sICAM\u20101 (soluble form of intercellular adhesion molecule\u20101)   Cell adhesion molecules and other matrix\u2010related proteins       110   SOD3 (superoxide dismutase)   Oxidative stress markers       111   STX\u20105 (syntaxin\u20105)   Other peptides/proteins shown to influence key events implicated in endometriosis       112   Survivin   Apoptosis markers       113   Thiols   Oxidative stress markers       114   TL (telomere length)   DNA\u2010repair/telomere maintenance molecules       115   T\u2010lymphocytes   Immune system and inflammatory markers   Immune cells   Peripheral blood mononuclear cells (PBMC)     116   TNF\u2010\u03b1 (tumour necrosis factor alpha)   Immune system and inflammatory markers   Other cytokines      117   Tregs (regulatory T cells)   Immune system and inflammatory markers   Immune cells   Peripheral blood mononuclear cells (PBMC)     118   TRX (thioredoxin)   Oxidative stress markers       119   Urocortin   Angiogenesis and growth factors and their receptors       120   VEGF (vascular endothelial growth factor)   Angiogenesis and growth factors and their receptors       121   Vitamin E   Oxidative stress markers       122   WBC (white blood cells)   Immune system and inflammatory markers   Immune cells   Peripheral blood mononuclear cells (PBMC)",
        "Appendix 2. Search strategy for MEDLINE (OVID platform)": "Database: MEDLINE (Ovid) <1946 to February, week 2 2015 (16.2.2015)>  Ovid MEDLINE(R) In\u2010Process & Other Non\u2010Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)  Search Strategy: \u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010 1 (biomarker$ or marker$).tw. (605002) 2 Laboratory Test$.tw. (29839) 3 growth factor$.tw. (272049) 4 scatter factor$.tw. (1287) 5 cytokine$.tw. (250618) 6 hepatocyte growth factor.tw. (8053) 7 (FGF or fibroblast growth factor$).tw. (31798) 8 (PDGF or platelet derived growth factor$).tw. (19864) 9 (EGF or epidermal growth factor$).tw. (58069) 10 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (43539) 11 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (281) 12 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (28842) 13 (EGFR or epidermal growth factor receptor$).tw. (41719) 14 (VEGF or vascular endothelial growth factor$).tw. (53588) 15 exp Luteinizing Hormone/bl (Blood] (24587) 16 leptin$.tw. (24994) 17 exp Progesterone/bl (Blood] (18412) 18 Proteolytic enzyme$.tw. (9768) 19 exp matrix metalloproteinase 1/ or exp matrix metalloproteinase 2/ or exp matrix metalloproteinase 3/ or exp matrix metalloproteinase 9/ (22968)  20 matrix metalloproteinase$.tw. (34522) 21 MMP$.tw. (44439) 22 TIMP$.tw. (10777) 23 exp \"tissue inhibitor of metalloproteinase\u20101\"/ or exp \"tissue inhibitor of metalloproteinase\u20102\"/ (6146)  24 exp Glycoproteins/ (637149) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (6761) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (4194) 27 (PP 14 or PP14).tw. (229) 28 serum placental protein$.tw. (33) 29 exp Follistatin/ (1134) 30 Osteopontin$.tw. (6769) 31 exp intercellular adhesion molecule\u20101/ or exp selectins/ (25302) 32 soluble intercellular adhesion.tw. (1588) 33 Soluble adhesion molecule$.tw. (779) 34 sICAM.tw. (2258) 35 sVCAM$.tw. (1277) 36 (sEcadherin or soluble E\u2010cadherin).tw. (95) 37 (sEselectin or soluble E\u2010selectin).tw. (689) 38 exp t\u2010lymphocytes/ or exp natural killer t\u2010cells/ (272580) 39 Immune cells alteration$.tw. (1) 40 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (21275) 41 Total complement level$.tw. (23) 42 Autoantibodies.tw. (33457) 43 exp Antibodies, Antiphospholipid/ (7522) 44 Anti\u2010endometrial.tw. (23) 45 Antiphospholipid$.tw. (9974) 46 exp hla antigens/ or exp hla\u2010a1 antigen/ or exp hla\u2010a2 antigen/ (64462) 47 (HLA or human leucocyte antigen$).tw. (80501) 48 Anti\u2010laminin\u20101.tw. (33) 49 Anti\u2010thyroid.tw. (1414) 50 Anti\u2010Thomsen Friedenreich antigen$.tw. (6) 51 Anti\u2010transferrin.tw. (275) 52 Anti\u2010LDL.tw. (181) 53 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (3) 54 interleukin$.tw. (175195) 55 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (44) 56 (MIF or migration inhibitory factor$).tw. (4479) 57 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (1344) 58 Fas ligand$.tw. (6032) 59 Endometrial marker$.tw. (11) 60 CAMs.tw. (1756) 61 cell adhesion molecule$.tw. (20903) 62 exp Integrins/ (44414) 63 Integrin$.tw. (39960) 64 Selectin$.tw. (55426) 65 Cadherin$.tw. (20780) 66 Aromatase P450.tw. (180) 67 estrogen receptor$.tw. (38819) 68 progesterone receptor$.tw. (16623) 69 MTMMP$.tw. (7) 70 cyr61.tw. (559) 71 exp Cysteine\u2010Rich Protein 61/ (386) 72 cysteine\u2010rich heparin\u2010binding protein$.tw. (9) 73 (ANXA 1 or ANXA1).tw. (313) 74 (Annexin 1 or Annexin1).tw. (339) 75 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2096) 76 serum marker$.tw. (5429) 77 neural marker$.tw. (925) 78 cell surface marker$.tw. (4456) 79 inflammatory marker$.tw. (10916) 80 microarray$.tw. (75404) 81 microRNA$.tw. (29731) 82 proteomic$.tw. (45292) 83 genomic$.tw. (190985) 84 (endometri$ adj2 biops$).tw. (3411) 85 Follistatin$.tw. (1663) 86 Vascular Endothelial Growth Factor A/ (35738) 87 Vitamin D\u2010Binding Protein/ (1282) 88 exp Cytokines/ (547522) 89 exp interleukins/ or exp interleukin\u20101/ or exp interleukin\u20106/ or exp interleukin\u20108/ or exp interleukin\u201012/ or exp interleukin\u201013/ (188479)  90 exp Epidermal Growth Factor/ (21298) 91 exp Fibroblast Growth Factors/ (25075) 92 Platelet\u2010Derived Growth Factor/ (11030) 93 Keratin\u201019/ (1090) 94 exp Clinical Laboratory Techniques/ (2132820) 95 (Luteinizing Hormone$ or LH).tw. (56679) 96 cytokeratin\u201019.tw. (1469) 97 (VDBP or vitamin D\u2010binding protein$).tw. (1158) 98 urinary peptide$.tw. (137) 99 VDBP\u2010Cr.tw. (1) 100 urinary VDBP corrected for creatinine expression.tw. (1) 101 urinary marker$.tw. (638) 102 or/1\u2010101 (4086291) 103 Endometriosis/di (Diagnosis] (3354) 104 102 or 103 (4088946) 105 exp Endometriosis/ (17244) 106 Endometrio$.tw. (21492) 107 105 or 106 (24940) 108 104 and 107 (10490) 109 (animals not (humans and animals)).sh. (3892900) 110 108 not 109 (10113) Additional search February 2015 \u2010 May 2015  Ovid MEDLINE(R) In\u2010Process & Other Non\u2010Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present (3.9.2015)>  Search Strategy: \u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010 1 (biomarker$ or marker$).tw. (652345) 2 Laboratory Test$.tw. (31389) 3 growth factor$.tw. (287701) 4 scatter factor$.tw. (1326) 5 cytokine$.tw. (267766) 6 hepatocyte growth factor.tw. (8585) 7 (FGF or fibroblast growth factor$).tw. (33674) 8 (PDGF or platelet derived growth factor$).tw. (20842) 9 (EGF or epidermal growth factor$).tw. (61625) 10 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (45386) 11 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (306) 12 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (30559) 13 (EGFR or epidermal growth factor receptor$).tw. (46446) 14 (VEGF or vascular endothelial growth factor$).tw. (58203) 15 exp Luteinizing Hormone/bl (Blood] (24870) 16 leptin$.tw. (26783) 17 exp Progesterone/bl (Blood] (18699) 18 Proteolytic enzyme$.tw. (9992) 19 exp matrix metalloproteinase 1/ or exp matrix metalloproteinase 2/ or exp matrix metalloproteinase 3/ or exp matrix metalloproteinase 9/ (24504)  20 matrix metalloproteinase$.tw. (37055) 21 MMP$.tw. (47849) 22 TIMP$.tw. (11419) 23 exp \"tissue inhibitor of metalloproteinase\u20101\"/ or exp \"tissue inhibitor of metalloproteinase\u20102\"/ (6447)  24 exp Glycoproteins/ (662211) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (7058) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (4399) 27 (PP 14 or PP14).tw. (232) 28 serum placental protein$.tw. (34) 29 exp Follistatin/ (1180) 30 Osteopontin$.tw. (7267) 31 exp intercellular adhesion molecule\u20101/ or exp selectins/ (26225) 32 soluble intercellular adhesion.tw. (1663) 33 Soluble adhesion molecule$.tw. (795) 34 sICAM.tw. (2374) 35 sVCAM$.tw. (1360) 36 (sEcadherin or soluble E\u2010cadherin).tw. (97) 37 (sEselectin or soluble E\u2010selectin).tw. (713) 38 exp t\u2010lymphocytes/ or exp natural killer t\u2010cells/ (284378) 39 Immune cells alteration$.tw. (1) 40 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (22494) 41 Total complement level$.tw. (24) 42 Autoantibodies.tw. (35161) 43 exp Antibodies, Antiphospholipid/ (7759) 44 Anti\u2010endometrial.tw. (22) 45 Antiphospholipid$.tw. (10351) 46 exp hla antigens/ or exp hla\u2010a1 antigen/ or exp hla\u2010a2 antigen/ (66724) 47 (HLA or human leucocyte antigen$).tw. (83856) 48 Anti\u2010laminin\u20101.tw. (33) 49 Anti\u2010thyroid.tw. (1478) 50 Anti\u2010Thomsen Friedenreich antigen$.tw. (8) 51 Anti\u2010transferrin.tw. (284) 52 Anti\u2010LDL.tw. (183) 53 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (3) 54 interleukin$.tw. (184697) 55 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (46) 56 (MIF or migration inhibitory factor$).tw. (4718) 57 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (1428) 58 Fas ligand$.tw. (6204) 59 Endometrial marker$.tw. (11) 60 CAMs.tw. (1823) 61 cell adhesion molecule$.tw. (22033) 62 exp Integrins/ (46487) 63 Integrin$.tw. (42447) 64 Selectin$.tw. (58540) 65 Cadherin$.tw. (22688) 66 Aromatase P450.tw. (182) 67 estrogen receptor$.tw. (41210) 68 progesterone receptor$.tw. (17437) 69 MTMMP$.tw. (7) 70 cyr61.tw. (620) 71 exp Cysteine\u2010Rich Protein 61/ (425) 72 cysteine\u2010rich heparin\u2010binding protein$.tw. (9) 73 (ANXA 1 or ANXA1).tw. (355) 74 (Annexin 1 or Annexin1).tw. (358) 75 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2190) 76 serum marker$.tw. (5721) 77 neural marker$.tw. (1026) 78 cell surface marker$.tw. (4751) 79 inflammatory marker$.tw. (12244) 80 microarray$.tw. (81764) 81 microRNA$.tw. (35967) 82 proteomic$.tw. (49911) 83 genomic$.tw. (205064) 84 (endometri$ adj2 biops$).tw. (3518) 85 Follistatin$.tw. (1762) 86 Vascular Endothelial Growth Factor A/ (38477) 87 Vitamin D\u2010Binding Protein/ (1356) 88 exp Cytokines/ (575020) 89 exp interleukins/ or exp interleukin\u20101/ or exp interleukin\u20106/ or exp interleukin\u20108/ or exp interleukin\u201012/ or exp interleukin\u201013/ (197567)  90 exp Epidermal Growth Factor/ (21875) 91 exp Fibroblast Growth Factors/ (26259) 92 Platelet\u2010Derived Growth Factor/ (11355) 93 Keratin\u201019/ (1179) 94 exp Clinical Laboratory Techniques/ (2203416) 95 (Luteinizing Hormone$ or LH).tw. (57796) 96 cytokeratin\u201019.tw. (1538) 97 (VDBP or vitamin D\u2010binding protein$).tw. (1262) 98 urinary peptide$.tw. (148) 99 VDBP\u2010Cr.tw. (1) 100 urinary VDBP corrected for creatinine expression.tw. (1) 101 urinary marker$.tw. (679) 102 or/1\u2010101 (4283825) 103 Endometriosis/di (Diagnosis] (3449) 104 102 or 103 (4286552) 105 exp Endometriosis/ (17833) 106 Endometrio$.tw. (22478) 107 105 or 106 (26003) 108 104 and 107 (10936) 109 (animals not (humans and animals)).sh. (4004321) 110 108 not 109 (10539) 111 (201501$ or 201502$ or 201503$ or 201504$).ed. (322721) 112 110 and 111 (215)",
        "Appendix 3. Search strategy for CENTRAL (OVID platform)": "Database: EBM Reviews \u2010 Cochrane Central Register of Controlled Trials <July 2015 (3.09.2015)>  Search Strategy: \u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010 1 (biomarker$ or marker$).tw. (23692) 2 Laboratory Test$.tw. (2793) 3 growth factor$.tw. (5448) 4 scatter factor$.tw. (8) 5 cytokine$.tw. (6264) 6 hepatocyte growth factor.tw. (111) 7 (FGF or fibroblast growth factor$).tw. (433) 8 (PDGF or platelet derived growth factor$).tw. (250) 9 (EGF or epidermal growth factor$).tw. (1077) 10 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (2132) 11 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (519) 12 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (236) 13 (EGFR or epidermal growth factor receptor$).tw. (1905) 14 (VEGF or vascular endothelial growth factor$).tw. (1532) 15 exp Luteinizing Hormone/bl (Blood] (151) 16 leptin$.tw. (1399) 17 exp Progesterone/bl (Blood] (58) 18 Proteolytic enzyme$.tw. (136) 19 exp matrix metalloproteinase 1/ or exp matrix metalloproteinase 2/ or exp matrix metalloproteinase 3/ or exp matrix metalloproteinase 9/ (292)  20 matrix metalloproteinase$.tw. (676) 21 MMP$.tw. (905) 22 TIMP$.tw. (229) 23 exp \"tissue inhibitor of metalloproteinase\u20101\"/ or exp \"tissue inhibitor of metalloproteinase\u20102\"/ (101)  24 exp Glycoproteins/ (10108) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (305) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (71) 27 (PP 14 or PP14).tw. (23) 28 serum placental protein$.tw. (6) 29 exp Follistatin/ (13) 30 Osteopontin$.tw. (80) 31 exp intercellular adhesion molecule\u20101/ or exp selectins/ (929) 32 soluble intercellular adhesion.tw. (256) 33 Soluble adhesion molecule$.tw. (89) 34 sICAM.tw. (319) 35 sVCAM$.tw. (223) 36 (sEcadherin or soluble E\u2010cadherin).tw. (4) 37 (sEselectin or soluble E\u2010selectin).tw. (99) 38 exp t\u2010lymphocytes/ or exp natural killer t\u2010cells/ (2645) 39 Immune cells alteration$.tw. (1) 40 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (445) 41 Total complement level$.tw. (0) 42 Autoantibodies.tw. (428) 43 exp Antibodies, Antiphospholipid/ (85) 44 Anti\u2010endometrial.tw. (0) 45 Antiphospholipid$.tw. (152) 46 exp hla antigens/ or exp hla\u2010a1 antigen/ or exp hla\u2010a2 antigen/ (563) 47 (HLA or human leucocyte antigen$).tw. (1724) 48 Anti\u2010laminin\u20101.tw. (0) 49 Anti\u2010thyroid.tw. (49) 50 Anti\u2010Thomsen Friedenreich antigen$.tw. (0) 51 Anti\u2010transferrin.tw. (0) 52 Anti\u2010LDL.tw. (3) 53 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (0) 54 interleukin$.tw. (7276) 55 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (0) 56 (MIF or migration inhibitory factor$).tw. (75) 57 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (3923) 58 Fas ligand$.tw. (47) 59 Endometrial marker$.tw. (2) 60 CAMs.tw. (53) 61 cell adhesion molecule$.tw. (568) 62 exp Integrins/ (781) 63 Integrin$.tw. (248) 64 Selectin$.tw. (2183) 65 Cadherin$.tw. (71) 66 Aromatase P450.tw. (3) 67 estrogen receptor$.tw. (1252) 68 progesterone receptor$.tw. (531) 69 MTMMP$.tw. (0) 70 cyr61.tw. (1) 71 exp Cysteine\u2010Rich Protein 61/ (1) 72 cysteine\u2010rich heparin\u2010binding protein$.tw. (0) 73 (ANXA 1 or ANXA1).tw. (3) 74 (Annexin 1 or Annexin1).tw. (2) 75 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (18) 76 serum marker$.tw. (411) 77 neural marker$.tw. (9) 78 cell surface marker$.tw. (46) 79 inflammatory marker$.tw. (1739) 80 microarray$.tw. (501) 81 microRNA$.tw. (103) 82 proteomic$.tw. (176) 83 genomic$.tw. (526) 84 (endometri$ adj2 biops$).tw. (464) 85 Follistatin$.tw. (26) 86 Vascular Endothelial Growth Factor A/ (560) 87 Vitamin D\u2010Binding Protein/ (18) 88 exp Cytokines/ (13960) 89 exp interleukins/ or exp interleukin\u20101/ or exp interleukin\u20106/ or exp interleukin\u20108/ or exp interleukin\u201012/ or exp interleukin\u201013/ (4413)  90 exp Epidermal Growth Factor/ (91) 91 exp Fibroblast Growth Factors/ (197) 92 Platelet\u2010Derived Growth Factor/ (99) 93 Keratin\u201019/ (19) 94 exp Clinical Laboratory Techniques/ (35164) 95 (Luteinizing Hormone$ or LH).tw. (2935) 96 cytokeratin\u201019.tw. (25) 97 (VDBP or vitamin D\u2010binding protein$).tw. (44) 98 urinary peptide$.tw. (8) 99 VDBP\u2010Cr.tw. (0) 100 urinary VDBP corrected for creatinine expression.tw. (0) 101 urinary marker$.tw. (67) 102 or/1\u2010101 (90390) 103 Endometriosis/di (Diagnosis] (6) 104 102 or 103 (90394) 105 exp Endometriosis/ (469) 106 Endometrio$.tw. (1026) 107 105 or 106 (1067) 108 104 and 107 (226) 109 (animals not (humans and animals)).sh. (1) 110 108 not 109 (226)",
        "Appendix 4. Search strategy for EMBASE (OVID platform)": "Database: EMBASE (Ovid) <1980 to 2015 Week 07 (16.02.2015)> Search strategy: \u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010 1 Laboratory Test$.tw. (41662) 2 growth factor$.tw. (318593) 3 scatter factor$.tw. (1388) 4 cytokine$.tw. (322134) 5 hepatocyte growth factor.tw. (9594) 6 (FGF or fibroblast growth factor$).tw. (37191) 7 (PDGF or platelet derived growth factor$).tw. (23530) 8 (EGF or epidermal growth factor$).tw. (69553) 9 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (49806) 10 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (542) 11 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (30820) 12 (EGFR or epidermal growth factor receptor$).tw. (64664) 13 (VEGF or vascular endothelial growth factor$).tw. (73191) 14 exp luteinizing hormone/ec (Endogenous Compound] (21924) 15 leptin$.tw. (32576) 16 exp progesterone blood level/ or exp progesterone urine level/ (6285) 17 Proteolytic enzyme$.tw. (9643) 18 exp matrix metalloproteinase/ (19364) 19 matrix metalloproteinase$.tw. (41445) 20 MMP$.tw. (58466) 21 TIMP$.tw. (14174) 22 exp \"tissue inhibitor of metalloproteinase 2\"/ (4824) 23 exp \"tissue inhibitor of metalloproteinase 1\"/ (8779) 24 exp glycoprotein/ec (Endogenous Compound] (246077) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (9536) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (6054) 27 (PP 14 or PP14).tw. (244) 28 serum placental protein$.tw. (43) 29 exp follistatin/ (2148) 30 Osteopontin$.tw. (8475) 31 exp intercellular adhesion molecule 1/ (32066) 32 exp selectin/ (3082) 33 soluble intercellular adhesion.tw. (1788) 34 Soluble adhesion molecule$.tw. (919) 35 sICAM.tw. (2888) 36 sVCAM$.tw. (1793) 37 (sEcadherin or soluble E\u2010cadherin).tw. (120) 38 (sEselectin or soluble E\u2010selectin).tw. (822) 39 exp T lymphocyte/ (374675) 40 exp natural killer T cell/ (5800) 41 Immune cells alteration$.tw. (6) 42 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (24786) 43 Total complement level$.tw. (20) 44 Autoantibodies.tw. (42037) 45 exp phospholipid antibody/ (9920) 46 Anti\u2010endometrial.tw. (23) 47 Antiphospholipid$.tw. (13777) 48 exp HLA antigen/ (81011) 49 exp HLA A1 antigen/ (597) 50 exp HLA A2 antigen/ (3288) 51 (HLA or human leucocyte antigen$).tw. (104497) 52 Anti\u2010laminin\u20101.tw. (43) 53 Anti\u2010thyroid.tw. (1873) 54 Anti\u2010Thomsen Friedenreich antigen$.tw. (5) 55 Anti\u2010transferrin.tw. (290) 56 Anti\u2010LDL.tw. (186) 57 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (4) 58 interleukin$.tw. (199692) 59 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (112) 60 (MIF or migration inhibitory factor$).tw. (5063) 61 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (5998) 62 Fas ligand$.tw. (6708) 63 Endometrial marker$.tw. (18) 64 CAMs.tw. (2100) 65 cell adhesion molecule$.tw. (24039) 66 exp integrin/ (29036) 67 Integrin$.tw. (48293) 68 Selectin$.tw. (67300) 69 Cadherin$.tw. (27150) 70 Aromatase P450.tw. (202) 71 estrogen receptor$.tw. (46656) 72 progesterone receptor$.tw. (19861) 73 MTMMP$.tw. (15) 74 cyr61.tw. (755) 75 exp cysteine rich protein 61/ (753) 76 cysteine\u2010rich heparin\u2010binding protein$.tw. (12) 77 (ANXA 1 or ANXA1).tw. (452) 78 (Annexin 1 or Annexin1).tw. (425) 79 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2620) 80 serum marker$.tw. (7720) 81 neural marker$.tw. (1119) 82 cell surface marker$.tw. (5851) 83 inflammatory marker$.tw. (17339) 84 microarray$.tw. (101846) 85 microRNA$.tw. (40082) 86 proteomic$.tw. (55191) 87 genomic$.tw. (217184) 88 (endometri$ adj2 biops$).tw. (4369) 89 Follistatin$.tw. (1945) 90 exp vasculotropin/ (69810) 91 Vascular Endothelial Growth Factor A.tw. (2275) 92 exp vitamin D binding protein/ (2064) 93 exp cytokine/ (1034772) 94 exp interleukin derivative/ (2790) 95 exp interleukin 1/ (48499) 96 exp interleukin 6/ (136328) 97 exp interleukin 8/ (48884) 98 exp interleukin 12/ (31842) 99 exp interleukin 13/ (13584) 100 exp epidermal growth factor/ (32130) 101 exp fibroblast growth factor/ (13858) 102 cytokeratin 19/ (3601) 103 platelet derived growth factor/ (18930) 104 cytokeratin\u201019.tw. (1918) 105 (VDBP or vitamin D\u2010binding protein$).tw. (1413) 106 urinary peptide$.tw. (174) 107 VDBP\u2010Cr.tw. (1) 108 urinary VDBP corrected for creatinine expression.tw. (1) 109 urinary marker$.tw. (830) 110 exp blood analysis/ (118854) 111 exp endometrium biopsy/ (4988) 112 exp urinalysis/ or exp biological marker/ (210153) 113 (biomarker or biomarkers).tw. (159748) 114 or/1\u2010113 (2734501) 115 endometriosis/di (Diagnosis] (4979) 116 114 or 115 (2738583) 117 exp endometriosis/ (25923) 118 Endometriosis.tw. (22110) 119 117 or 118 (27911) 120 116 and 119 (10326) 121 Animal/ not Human/ (1204497) 122 120 not 121 (10279) Additional search February 2015 \u2010 May 2015  Embase <1980 to 2015 Week 35 (3.09.2015)> Search Strategy: \u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010 1 Laboratory Test$.tw. (44290) 2 growth factor$.tw. (335543) 3 scatter factor$.tw. (1407) 4 cytokine$.tw. (343623) 5 hepatocyte growth factor.tw. (10104) 6 (FGF or fibroblast growth factor$).tw. (39159) 7 (PDGF or platelet derived growth factor$).tw. (24591) 8 (EGF or epidermal growth factor$).tw. (73599) 9 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (51838) 10 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (583) 11 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (32580) 12 (EGFR or epidermal growth factor receptor$).tw. (71526) 13 (VEGF or vascular endothelial growth factor$).tw. (79087) 14 exp luteinizing hormone/ec (Endogenous Compound] (22767) 15 leptin$.tw. (34921) 16 exp progesterone blood level/ or exp progesterone urine level/ (6534) 17 Proteolytic enzyme$.tw. (9903) 18 exp matrix metalloproteinase/ (20462) 19 matrix metalloproteinase$.tw. (44380) 20 MMP$.tw. (63208) 21 TIMP$.tw. (15146) 22 exp \"tissue inhibitor of metalloproteinase 2\"/ (5136) 23 exp \"tissue inhibitor of metalloproteinase 1\"/ (9381) 24 exp glycoprotein/ec (Endogenous Compound] (260024) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (10051) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (6446) 27 (PP 14 or PP14).tw. (243) 28 serum placental protein$.tw. (44) 29 exp follistatin/ (2283) 30 Osteopontin$.tw. (9173) 31 exp intercellular adhesion molecule 1/ (33492) 32 exp selectin/ (3217) 33 soluble intercellular adhesion.tw. (1865) 34 Soluble adhesion molecule$.tw. (944) 35 sICAM.tw. (3049) 36 sVCAM$.tw. (1924) 37 (sEcadherin or soluble E\u2010cadherin).tw. (125) 38 (sEselectin or soluble E\u2010selectin).tw. (861) 39 exp T lymphocyte/ (394405) 40 exp natural killer T cell/ (6310) 41 Immune cells alteration$.tw. (6) 42 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (26082) 43 Total complement level$.tw. (20) 44 Autoantibodies.tw. (44153) 45 exp phospholipid antibody/ (10362) 46 Anti\u2010endometrial.tw. (25) 47 Antiphospholipid$.tw. (14399) 48 exp HLA antigen/ (83748) 49 exp HLA A1 antigen/ (622) 50 exp HLA A2 antigen/ (3409) 51 (HLA or human leucocyte antigen$).tw. (109332) 52 Anti\u2010laminin\u20101.tw. (43) 53 Anti\u2010thyroid.tw. (2059) 54 Anti\u2010Thomsen Friedenreich antigen$.tw. (7) 55 Anti\u2010transferrin.tw. (297) 56 Anti\u2010LDL.tw. (191) 57 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (4) 58 interleukin$.tw. (210083) 59 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (114) 60 (MIF or migration inhibitory factor$).tw. (5342) 61 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (6488) 62 Fas ligand$.tw. (6895) 63 Endometrial marker$.tw. (18) 64 CAMs.tw. (2198) 65 cell adhesion molecule$.tw. (25207) 66 exp integrin/ (30330) 67 Integrin$.tw. (50938) 68 Selectin$.tw. (71624) 69 Cadherin$.tw. (29496) 70 Aromatase P450.tw. (207) 71 estrogen receptor$.tw. (49530) 72 progesterone receptor$.tw. (21068) 73 MTMMP$.tw. (16) 74 cyr61.tw. (822) 75 exp cysteine rich protein 61/ (829) 76 cysteine\u2010rich heparin\u2010binding protein$.tw. (12) 77 (ANXA 1 or ANXA1).tw. (500) 78 (Annexin 1 or Annexin1).tw. (440) 79 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2760) 80 serum marker$.tw. (8158) 81 neural marker$.tw. (1234) 82 cell surface marker$.tw. (6222) 83 inflammatory marker$.tw. (19492) 84 microarray$.tw. (110181) 85 microRNA$.tw. (47554) 86 proteomic$.tw. (60599) 87 genomic$.tw. (233444) 88 (endometri$ adj2 biops$).tw. (4589) 89 Follistatin$.tw. (2081) 90 exp vasculotropin/ (74115) 91 Vascular Endothelial Growth Factor A.tw. (2526) 92 exp vitamin D binding protein/ (2196) 93 exp cytokine/ (1094317) 94 exp interleukin derivative/ (3281) 95 exp interleukin 1/ (50850) 96 exp interleukin 6/ (147379) 97 exp interleukin 8/ (52281) 98 exp interleukin 12/ (33479) 99 exp interleukin 13/ (14685) 100 exp epidermal growth factor/ (33057) 101 exp fibroblast growth factor/ (14499) 102 cytokeratin 19/ (3886) 103 platelet derived growth factor/ (19655) 104 cytokeratin\u201019.tw. (2030) 105 (VDBP or vitamin D\u2010binding protein$).tw. (1520) 106 urinary peptide$.tw. (189) 107 VDBP\u2010Cr.tw. (1) 108 urinary VDBP corrected for creatinine expression.tw. (1) 109 urinary marker$.tw. (883) 110 exp blood analysis/ (124468) 111 exp endometrium biopsy/ (5197) 112 exp urinalysis/ or exp biological marker/ (232619) 113 (biomarker or biomarkers).tw. (182609) 114 or/1\u2010113 (2911073) 115 endometriosis/di (Diagnosis] (5173) 116 114 or 115 (2915302) 117 exp endometriosis/ (27433) 118 Endometriosis.tw. (23449) 119 117 or 118 (29532) 120 116 and 119 (10922) 121 Animal/ not Human/ (1261620) 122 120 not 121 (10862) 123 (201501$ or 201502$ or 201503$ or 201504$).em. (49200) 124 122 and 123 (34)",
        "Database: EMBASE (Ovid) <1980 to 2015 Week 07 (16.02.2015)>": "Search strategy: \u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010 1 Laboratory Test$.tw. (41662) 2 growth factor$.tw. (318593) 3 scatter factor$.tw. (1388) 4 cytokine$.tw. (322134) 5 hepatocyte growth factor.tw. (9594) 6 (FGF or fibroblast growth factor$).tw. (37191) 7 (PDGF or platelet derived growth factor$).tw. (23530) 8 (EGF or epidermal growth factor$).tw. (69553) 9 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (49806) 10 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (542) 11 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (30820) 12 (EGFR or epidermal growth factor receptor$).tw. (64664) 13 (VEGF or vascular endothelial growth factor$).tw. (73191) 14 exp luteinizing hormone/ec (Endogenous Compound] (21924) 15 leptin$.tw. (32576) 16 exp progesterone blood level/ or exp progesterone urine level/ (6285) 17 Proteolytic enzyme$.tw. (9643) 18 exp matrix metalloproteinase/ (19364) 19 matrix metalloproteinase$.tw. (41445) 20 MMP$.tw. (58466) 21 TIMP$.tw. (14174) 22 exp \"tissue inhibitor of metalloproteinase 2\"/ (4824) 23 exp \"tissue inhibitor of metalloproteinase 1\"/ (8779) 24 exp glycoprotein/ec (Endogenous Compound] (246077) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (9536) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (6054) 27 (PP 14 or PP14).tw. (244) 28 serum placental protein$.tw. (43) 29 exp follistatin/ (2148) 30 Osteopontin$.tw. (8475) 31 exp intercellular adhesion molecule 1/ (32066) 32 exp selectin/ (3082) 33 soluble intercellular adhesion.tw. (1788) 34 Soluble adhesion molecule$.tw. (919) 35 sICAM.tw. (2888) 36 sVCAM$.tw. (1793) 37 (sEcadherin or soluble E\u2010cadherin).tw. (120) 38 (sEselectin or soluble E\u2010selectin).tw. (822) 39 exp T lymphocyte/ (374675) 40 exp natural killer T cell/ (5800) 41 Immune cells alteration$.tw. (6) 42 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (24786) 43 Total complement level$.tw. (20) 44 Autoantibodies.tw. (42037) 45 exp phospholipid antibody/ (9920) 46 Anti\u2010endometrial.tw. (23) 47 Antiphospholipid$.tw. (13777) 48 exp HLA antigen/ (81011) 49 exp HLA A1 antigen/ (597) 50 exp HLA A2 antigen/ (3288) 51 (HLA or human leucocyte antigen$).tw. (104497) 52 Anti\u2010laminin\u20101.tw. (43) 53 Anti\u2010thyroid.tw. (1873) 54 Anti\u2010Thomsen Friedenreich antigen$.tw. (5) 55 Anti\u2010transferrin.tw. (290) 56 Anti\u2010LDL.tw. (186) 57 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (4) 58 interleukin$.tw. (199692) 59 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (112) 60 (MIF or migration inhibitory factor$).tw. (5063) 61 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (5998) 62 Fas ligand$.tw. (6708) 63 Endometrial marker$.tw. (18) 64 CAMs.tw. (2100) 65 cell adhesion molecule$.tw. (24039) 66 exp integrin/ (29036) 67 Integrin$.tw. (48293) 68 Selectin$.tw. (67300) 69 Cadherin$.tw. (27150) 70 Aromatase P450.tw. (202) 71 estrogen receptor$.tw. (46656) 72 progesterone receptor$.tw. (19861) 73 MTMMP$.tw. (15) 74 cyr61.tw. (755) 75 exp cysteine rich protein 61/ (753) 76 cysteine\u2010rich heparin\u2010binding protein$.tw. (12) 77 (ANXA 1 or ANXA1).tw. (452) 78 (Annexin 1 or Annexin1).tw. (425) 79 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2620) 80 serum marker$.tw. (7720) 81 neural marker$.tw. (1119) 82 cell surface marker$.tw. (5851) 83 inflammatory marker$.tw. (17339) 84 microarray$.tw. (101846) 85 microRNA$.tw. (40082) 86 proteomic$.tw. (55191) 87 genomic$.tw. (217184) 88 (endometri$ adj2 biops$).tw. (4369) 89 Follistatin$.tw. (1945) 90 exp vasculotropin/ (69810) 91 Vascular Endothelial Growth Factor A.tw. (2275) 92 exp vitamin D binding protein/ (2064) 93 exp cytokine/ (1034772) 94 exp interleukin derivative/ (2790) 95 exp interleukin 1/ (48499) 96 exp interleukin 6/ (136328) 97 exp interleukin 8/ (48884) 98 exp interleukin 12/ (31842) 99 exp interleukin 13/ (13584) 100 exp epidermal growth factor/ (32130) 101 exp fibroblast growth factor/ (13858) 102 cytokeratin 19/ (3601) 103 platelet derived growth factor/ (18930) 104 cytokeratin\u201019.tw. (1918) 105 (VDBP or vitamin D\u2010binding protein$).tw. (1413) 106 urinary peptide$.tw. (174) 107 VDBP\u2010Cr.tw. (1) 108 urinary VDBP corrected for creatinine expression.tw. (1) 109 urinary marker$.tw. (830) 110 exp blood analysis/ (118854) 111 exp endometrium biopsy/ (4988) 112 exp urinalysis/ or exp biological marker/ (210153) 113 (biomarker or biomarkers).tw. (159748) 114 or/1\u2010113 (2734501) 115 endometriosis/di (Diagnosis] (4979) 116 114 or 115 (2738583) 117 exp endometriosis/ (25923) 118 Endometriosis.tw. (22110) 119 117 or 118 (27911) 120 116 and 119 (10326) 121 Animal/ not Human/ (1204497) 122 120 not 121 (10279) Additional search February 2015 \u2010 May 2015  Embase <1980 to 2015 Week 35 (3.09.2015)> Search Strategy: \u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010 1 Laboratory Test$.tw. (44290) 2 growth factor$.tw. (335543) 3 scatter factor$.tw. (1407) 4 cytokine$.tw. (343623) 5 hepatocyte growth factor.tw. (10104) 6 (FGF or fibroblast growth factor$).tw. (39159) 7 (PDGF or platelet derived growth factor$).tw. (24591) 8 (EGF or epidermal growth factor$).tw. (73599) 9 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (51838) 10 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (583) 11 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (32580) 12 (EGFR or epidermal growth factor receptor$).tw. (71526) 13 (VEGF or vascular endothelial growth factor$).tw. (79087) 14 exp luteinizing hormone/ec (Endogenous Compound] (22767) 15 leptin$.tw. (34921) 16 exp progesterone blood level/ or exp progesterone urine level/ (6534) 17 Proteolytic enzyme$.tw. (9903) 18 exp matrix metalloproteinase/ (20462) 19 matrix metalloproteinase$.tw. (44380) 20 MMP$.tw. (63208) 21 TIMP$.tw. (15146) 22 exp \"tissue inhibitor of metalloproteinase 2\"/ (5136) 23 exp \"tissue inhibitor of metalloproteinase 1\"/ (9381) 24 exp glycoprotein/ec (Endogenous Compound] (260024) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (10051) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (6446) 27 (PP 14 or PP14).tw. (243) 28 serum placental protein$.tw. (44) 29 exp follistatin/ (2283) 30 Osteopontin$.tw. (9173) 31 exp intercellular adhesion molecule 1/ (33492) 32 exp selectin/ (3217) 33 soluble intercellular adhesion.tw. (1865) 34 Soluble adhesion molecule$.tw. (944) 35 sICAM.tw. (3049) 36 sVCAM$.tw. (1924) 37 (sEcadherin or soluble E\u2010cadherin).tw. (125) 38 (sEselectin or soluble E\u2010selectin).tw. (861) 39 exp T lymphocyte/ (394405) 40 exp natural killer T cell/ (6310) 41 Immune cells alteration$.tw. (6) 42 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (26082) 43 Total complement level$.tw. (20) 44 Autoantibodies.tw. (44153) 45 exp phospholipid antibody/ (10362) 46 Anti\u2010endometrial.tw. (25) 47 Antiphospholipid$.tw. (14399) 48 exp HLA antigen/ (83748) 49 exp HLA A1 antigen/ (622) 50 exp HLA A2 antigen/ (3409) 51 (HLA or human leucocyte antigen$).tw. (109332) 52 Anti\u2010laminin\u20101.tw. (43) 53 Anti\u2010thyroid.tw. (2059) 54 Anti\u2010Thomsen Friedenreich antigen$.tw. (7) 55 Anti\u2010transferrin.tw. (297) 56 Anti\u2010LDL.tw. (191) 57 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (4) 58 interleukin$.tw. (210083) 59 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (114) 60 (MIF or migration inhibitory factor$).tw. (5342) 61 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (6488) 62 Fas ligand$.tw. (6895) 63 Endometrial marker$.tw. (18) 64 CAMs.tw. (2198) 65 cell adhesion molecule$.tw. (25207) 66 exp integrin/ (30330) 67 Integrin$.tw. (50938) 68 Selectin$.tw. (71624) 69 Cadherin$.tw. (29496) 70 Aromatase P450.tw. (207) 71 estrogen receptor$.tw. (49530) 72 progesterone receptor$.tw. (21068) 73 MTMMP$.tw. (16) 74 cyr61.tw. (822) 75 exp cysteine rich protein 61/ (829) 76 cysteine\u2010rich heparin\u2010binding protein$.tw. (12) 77 (ANXA 1 or ANXA1).tw. (500) 78 (Annexin 1 or Annexin1).tw. (440) 79 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2760) 80 serum marker$.tw. (8158) 81 neural marker$.tw. (1234) 82 cell surface marker$.tw. (6222) 83 inflammatory marker$.tw. (19492) 84 microarray$.tw. (110181) 85 microRNA$.tw. (47554) 86 proteomic$.tw. (60599) 87 genomic$.tw. (233444) 88 (endometri$ adj2 biops$).tw. (4589) 89 Follistatin$.tw. (2081) 90 exp vasculotropin/ (74115) 91 Vascular Endothelial Growth Factor A.tw. (2526) 92 exp vitamin D binding protein/ (2196) 93 exp cytokine/ (1094317) 94 exp interleukin derivative/ (3281) 95 exp interleukin 1/ (50850) 96 exp interleukin 6/ (147379) 97 exp interleukin 8/ (52281) 98 exp interleukin 12/ (33479) 99 exp interleukin 13/ (14685) 100 exp epidermal growth factor/ (33057) 101 exp fibroblast growth factor/ (14499) 102 cytokeratin 19/ (3886) 103 platelet derived growth factor/ (19655) 104 cytokeratin\u201019.tw. (2030) 105 (VDBP or vitamin D\u2010binding protein$).tw. (1520) 106 urinary peptide$.tw. (189) 107 VDBP\u2010Cr.tw. (1) 108 urinary VDBP corrected for creatinine expression.tw. (1) 109 urinary marker$.tw. (883) 110 exp blood analysis/ (124468) 111 exp endometrium biopsy/ (5197) 112 exp urinalysis/ or exp biological marker/ (232619) 113 (biomarker or biomarkers).tw. (182609) 114 or/1\u2010113 (2911073) 115 endometriosis/di (Diagnosis] (5173) 116 114 or 115 (2915302) 117 exp endometriosis/ (27433) 118 Endometriosis.tw. (23449) 119 117 or 118 (29532) 120 116 and 119 (10922) 121 Animal/ not Human/ (1261620) 122 120 not 121 (10862) 123 (201501$ or 201502$ or 201503$ or 201504$).em. (49200) 124 122 and 123 (34)",
        "Appendix 5. Search strategy for CINAHL database (EBSCO platform)": "Database: CINAHL Plus with Full Text (EBSCOhost) <1980 to 20.04.2015>  Search strategy:        #   Query   Results     S97   S3 AND S96   1131     S96   S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62 OR S63 OR S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78 OR S79 OR S80 OR S81 OR S82 OR S83 OR S84 OR S85 OR S86 OR S87 OR S88 OR S89 OR S90 OR S91 OR S92 OR S93 OR S94 OR S95    341775     S95   TX urinary peptide*   1598     S94   TX (VDBP or vitamin D\u2010binding protein*)   134     S93   TX cytokeratin\u201019   109     S92   TX (Luteinizing Hormone* or LH)   18041     S91   (MH \"Diagnosis, Laboratory+\")   101773     S90   \"Keratin\u201019\"   2     S89   (MH \"Platelet\u2010Derived Growth Factor\")   394     S88   (MH \"Epidermal Growth Factors\")   1264     S87   (MH \"Interleukins\")   6584     S86   (MH \"Cytokines\")   6860     S85   TX Vitamin D\u2010Binding Protein   131     S84   (MH \"Vascular Endothelial Growth Factor A\")   194     S83   TX (endometri* N2 biops*)   432     S82   TX (endometri* adj2 biops*)   0     S81   TX genomic$   7487     S80   TX proteomic*   2434     S79   TX microRNA   824     S78   TX microarray   3123     S77   TX (PGP 95 or PGP95 or protein gene product*)   9925     S76   TX (Annexin 1 or Annexin1)   472     S75   TX (ANXA 1 or ANXA1)   41     S74   TX cysteine\u2010rich heparin\u2010binding protein*   12     S73   (MH \"Protein Array Analysis\")   73     S72   TX cyr61   34     S71   TX MTMMP*   0     S70   TX progesterone receptor*   1927     S69   TX estrogen receptor*   5193     S68   TX Aromatase P450   38     S67   TX Cadherin*   900     S66   TX Selectin*   28411     S65   TX Integrin*   1587     S64   TX cell adhesion molecule*   1578     S63   TX CAMs   550     S62   TX Endometrial marker*   54     S61   TX Fas ligand   338     S60   TX (TNF\u2010a or tumour necrosis factor* alfa)   1489     S59   TX (MIF or migration inhibitory factor*)   399     S58   TX (MCP\u2010I or monocyte chemoattractant protein\u2010I)   13     S57   TX interleukin   13809     S56   TX (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein)   7     S55   TX Anti\u2010LDL   9     S54   TX Anti\u2010transferrin   3     S53   TX Anti\u2010Thomsen Friedenreich antigen*   1     S52   TX Anti\u2010thyroid   109     S51   TX Anti\u2010laminin\u20101   15     S50   TX (HLA or human leucocyte antigen*)   4202     S49   (MM \"HLA Antigens\")   638     S48   TX Antiphospholipid*   1249     S47   TX Anti\u2010endometrial   34     S46   (MH \"Antibodies/BL/DU\")   1294     S45   TX Autoantibodies   4385     S43   TX Total complement level   3     S42   TX (T helper* or T supressor*)   2341     S41   TX Immune cells alteration*   24     S40   TX natural killer t\u2010cells   669     S39   (MM \"T Lymphocytes\")   2404     S38   TX (sEselectin or soluble E\u2010selectin)   91     S37   TX (sEcadherin or soluble E\u2010cadherin)   8     S36   TX sVCAM   100     S35   TX sICAM   173     S34   TX Soluble adhesion molecule   368     S33   TX soluble intercellular adhesion   237     S32   (MM \"Cell Adhesion Molecules\")   52     S31   TX Osteopontin*   416     S30   TX Follistatin   74     S29   TX serum placental protein*   11     S28   TX (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109)   262     S27   TX (Ca\u2010125 or Ca125 or cancer antigen 125)   831     S26   (MM \"Glycoproteins/BL/DU\")   224     S25   TX tissue inhibitor of metalloproteinase   423     S24   TX TIMP*   1845     S23   TX MMP*   4244     S22   TX matrix metalloproteinase*   3325     S21   TX Proteolytic enzyme*   1461     S20   (MM \"Progesterone/BL/DU\")   51     S19   TX leptin*   3258     S18   (MM \"Luteinizing Hormone/BL/DU\")   38     S17   TX (VEGF or vascular endothelial growth factor*)   7166     S16   TX (EGFR or epidermal growth factor receptor*)   6188     S15   TX (TGF\u2010b or transforming growth factor beta or TGFb)   2972     S14   TX (TGF\u2010a or transforming growth factor alfa or TGFa)   464     S13   TX (IGF\u2010I or insulin\u2010like growth factor* or IGF1)   3588     S12   TX (EGF or epidermal growth factor*)   6250     S11   TX (PDGF or platelet derived growth factor*)   3195     S10   TX (FGF or fibroblast growth factor*)   3395     S9   TX hepatocyte growth factor*   880     S8   TX cytokine*   20821     S7   TX scatter factor*   1864     S6   TX growth factor*   76163     S5   TX Laboratory Test*   82732     S4   TX (biomarker* or marker*)   84857     S3   S1 OR S2   2841     S2   TX Endometrio*   2841     S1   (MM \"Endometriosis\")   889     S4   TX (biomarker* or marker*)   61,794     S3   S1 OR S2   2,174     S2   TX Endometrio*   2,174     S1   (MM \"Endometriosis\")   1,306",
        "Appendix 6. Search strategy for other databases": "Search for clinical studies Database: Web of Science Core Collection (Thomson Reuters) <1900 to Present (20.04.2015)>  Search strategy: 1. Topic=(endometrio*) AND Topic=(diagnos* OR test* OR marker* OR biomarker*); Timespan=All Years (7425)  Database: PsycINFO (Ovid) <1806 to April Week 2 2015 (20.04.2015)>  Search strategy: 1. endometriosis.tw. (174) Database: LILACS <20.04.2015>  Search strategy: 1. (tw:(endometriosis)) AND (tw:(diagnos*)) (420) Database: OAIster (WorldCat.org) <20.04.2015>  Search strategy: 1. endometriosis and (marker* or biomarker*) (11) 2. endometriosis and diagnos* (446) Database: TRIP <20.04.2015>  Search strategy: 1. (endometriosis and diagnos*) (1648)   Searches of trial registers for ongoing and registered trials Database: 'ClinicalTrials.gov', a service of the US national Institute of Health  Search strategy: 1. endometriosis (220) 2. endometriosis AND diagnosis (22) Database: WHO International Clinical Trials Registry Platform (ICTRP) <20.04.2015>  Search strategy: 1. endometriosis (523)   Searches for the reviews as potential source of references  Database: MEDION <10.01.2014> Search strategy: ICP Code female genital system (including breast), Signssymp medical imaging, laboratory tests, histology and cytology, endoscopy and laparoscopy. Filter: systematic reviews of diagnostic studies (2)  Database: DARE (CRD) <20.04.2015>  Search strategy: 1. endometriosis (99) PubMed, a \u2018Systematic Review\u2019 search under the \u2018Clinical Queries\u2019 link <20.04.2015>  Search strategy: (endometriosis) AND systematic(sb] (418) Category: Diagnosis; Scope: Broad    Searches for the papers recently published and not yet indexed in the major databases Search engine: PubMed <20.10.2014 to 20.04.2015>  Search strategy:        1. marker (14979) 2. test (61151) 3. diagnos* (69743) 4. biomarker (10806) 5. or/1\u20104 (7943) Filters: Publication date from 2014/10/20 to 2015/04/20   Index test(s) set     6. Endometriosis (584) Filters: Publication date from 2014/10/20 to 2015/04/20   Target condition set     7. 5 and 6 (267) Filters: Publication date from 2014/10/20 to 2015/04/20   Combined sets",
        "Search for clinical studies": "Database: Web of Science Core Collection (Thomson Reuters) <1900 to Present (20.04.2015)>  Search strategy: 1. Topic=(endometrio*) AND Topic=(diagnos* OR test* OR marker* OR biomarker*); Timespan=All Years (7425)  Database: PsycINFO (Ovid) <1806 to April Week 2 2015 (20.04.2015)>  Search strategy: 1. endometriosis.tw. (174) Database: LILACS <20.04.2015>  Search strategy: 1. (tw:(endometriosis)) AND (tw:(diagnos*)) (420) Database: OAIster (WorldCat.org) <20.04.2015>  Search strategy: 1. endometriosis and (marker* or biomarker*) (11) 2. endometriosis and diagnos* (446) Database: TRIP <20.04.2015>  Search strategy: 1. (endometriosis and diagnos*) (1648)",
        "Searches of trial registers for ongoing and registered trials": "Database: 'ClinicalTrials.gov', a service of the US national Institute of Health  Search strategy: 1. endometriosis (220) 2. endometriosis AND diagnosis (22) Database: WHO International Clinical Trials Registry Platform (ICTRP) <20.04.2015>  Search strategy: 1. endometriosis (523)",
        "Searches for the reviews as potential source of references": "Database: MEDION <10.01.2014> Search strategy: ICP Code female genital system (including breast), Signssymp medical imaging, laboratory tests, histology and cytology, endoscopy and laparoscopy. Filter: systematic reviews of diagnostic studies (2)  Database: DARE (CRD) <20.04.2015>  Search strategy: 1. endometriosis (99) PubMed, a \u2018Systematic Review\u2019 search under the \u2018Clinical Queries\u2019 link <20.04.2015>  Search strategy: (endometriosis) AND systematic(sb] (418) Category: Diagnosis; Scope: Broad",
        "Database: MEDION <10.01.2014>": "Search strategy: ICP Code female genital system (including breast), Signssymp medical imaging, laboratory tests, histology and cytology, endoscopy and laparoscopy. Filter: systematic reviews of diagnostic studies (2)  Database: DARE (CRD) <20.04.2015>  Search strategy: 1. endometriosis (99) PubMed, a \u2018Systematic Review\u2019 search under the \u2018Clinical Queries\u2019 link <20.04.2015>  Search strategy: (endometriosis) AND systematic(sb] (418) Category: Diagnosis; Scope: Broad",
        "Searches for the papers recently published and not yet indexed in the major databases": "Search engine: PubMed <20.10.2014 to 20.04.2015>  Search strategy:        1. marker (14979) 2. test (61151) 3. diagnos* (69743) 4. biomarker (10806) 5. or/1\u20104 (7943) Filters: Publication date from 2014/10/20 to 2015/04/20   Index test(s) set     6. Endometriosis (584) Filters: Publication date from 2014/10/20 to 2015/04/20   Target condition set     7. 5 and 6 (267) Filters: Publication date from 2014/10/20 to 2015/04/20   Combined sets",
        "Appendix 7. Summary of findings table 2: Blood biomarkers that do not distinguish between women with and without endometriosis": "Review question    Which blood biomarkers are unlikely to serve a basis of the diagnostic test for endometriosis?      Importance    Biomarkers that do not show differential expression in women with and without endometriosis, are unlikely to be diagnostically useful. Information regarding negative trials can focus research on better diagnostic targets.The biomarkers that display conflicting results (distinguish women with and without endometriosis in some but not all studies) can be identified and reported on. Studies that did not show differential expression of a biomarker in endometriosis but were adequately designed and that met inclusion criteria for this review were included       Patients    Reproductive\u2010aged women with suspected endometriosis or persistent ovarian mass, or women undergoing infertility work\u2010up/gynaecological laparoscopy       Settings    Hospitals (public or private of any level), outpatient clinics (general gynaecology, reproductive medicine, pelvic pain) or research laboratory       Reference standard    Visualisation of endometriosis at surgery (laparoscopy or laparotomy) with or without histological confirmation       Study design    Cross\u2010sectional of a single\u2010gate design (N = 39) or two\u2010gate design (N = 41); unable to determine if single\u2010 or two\u2010gate design for 2 studies; prospective enrolment; a single study could assess more than one test       Risk of bias     Overall judgement   Poor quality (no studies had 'low risk' assessment in all 4 domains)     Patient selection bias   High risk: 50 studies; unclear risk: 25 studies; low risk: 7 studies     Index test interpretation bias   High risk: 80 studies; unclear risk: 2 studies; low risk: 0 studies     Reference standard interpretation bias   High risk: 0 studies; unclear risk: 29 studies; low risk: 53 studies     Flow and timing selection bias   High risk: 12 studies; unclear risk: 7 studies; low risk: 63 studies      Applicability concerns    Concerns regarding patient selection   High concern: 45 studies, unclear concern: 5 studies; low concern: 32 studies     Concerns regarding index test   High concern: 0 studies, unclear concern: 1 study; low concern: 81 studies     Concerns regarding reference standard   High concern: 0 studies; unclear concern: 0 studies; low concern: 82 studies      Biomarker     Number of participants     Units     Outcome measures     rASRM stage     Menstrual cycle phase     Reference       Endometriosis     Controls     Expression in endometriosis     Expression in controls     P value      1. Angiogenesis and growth factors and their receptors       1.1. angiogenic activity of serum   52   32   mean \u00b1 SD, number of newly formed blood vessels   13.57 \u00b1 1.68   13.43 \u00b1 1.29   NS   I\u2010IV   follicular   Barcz 2002      1.2. CAC (circulating angiogenic cells)   42   22   mean \u00b1 SEM, %   0.084 \u00b1 0.007   0.072 \u00b1 0.009   0.32   I\u2010IV   any   Webster 2013      1.3. EGF (epidermal growth factor)   36   36   mean \u00b1 SD, pg/ml   NS      Philippoussis 2004      497.8 \u00b1 99.1   490.5 \u00b1 191.2     NS      493.4 \u00b1 180.4   494.4 \u00b1 169.8     1.4. sEGF\u2010R (soluble epidermal growth factor\u2010receptor)   28   20    below detection limit of assay   below detection limit of assay    I\u2010IV   n/a   Matalliotakis 2003a      1.5. sFlt\u20101 (sVEGFR\u20101] (soluble fms\u2010like tyrosine kinase or (variant of VEGF receptor 1])    46   24   mean \u00b1 SEM, pg/ml   119.89 \u00b1 5.43   112.30 \u00b1 5.23   NS   I\u2010IV   follicular/ luteal   Cho 2007      1.6.a.glycodelin A (PP14 or PAEP] ((placental protein 14 or progestogen\u2010associated endometrial protein])    33   17   mean \u00b1 SD, ng/ml   44.21 \u00b1 45.67   34.55 \u00b1 58.13   0.19   I\u2010IV   follicular   Drosdzol\u2010Cop 2012a      1.6.b. PAEP (glycodelin] (Progestagen\u2010associated endometrial protein)   36   19   mean \u00b1 SE, U/ml   follicular cycle phase: 5\u00b12 (rASRM I\u2010II); 10\u00b12 (rASRM III\u2010IV); luteal cycle phase: 18\u00b14 (rASRM I\u2010II); 23\u00b14 (rASRM III\u2010IV)   follicular cycle phase: 9 \u00b1 3; luteal cycle phase: 23 \u00b1 6   NS   I\u2010IV   follicular/ luteal   Joshi 1986      1.6.c. glycodelin A (PP14 or PAEP] ((placental protein 14 or progestogen\u2010associated endometrial protein])    69   32    below detection limit of assay   below detection limit of assay    I\u2010IV   n/a   Paiva 2014      1.7. HGF (hepatocyte growth factor)   37   21   mean \u00b1 SD, pg/ml   6879 \u00b1 53.3   675.19 \u00b1 40.9   NS   I\u2010IV   follicular/ luteal   Khan 2006      1.8.a. sIGF\u20101 (soluble Insulin\u2010like growth factor\u20101)   28   20   %OD increase over background \u00b1 S.E.M   275 \u00b1 50   300 \u00b1 33.3   NS   I\u2010IV   n/a   Matalliotakis 2003a      1.8.b. IGF\u20101 (insulin\u2010like growth factor\u20101)   77   71   mean \u00b1 SD, ng/ml   crude values   NS   I\u2010IV   follicular/ luteal   Steff 2004b      follicular cycle phase: 269.1 \u00b1 90.3; luteal cycle phase: 290.2 \u00b1 93.3   follicular cycle phase: 270.1 \u00b1 91.7; luteal cycle phase: 271.6 \u00b1 76.8     adjusted values (age, BMI using a univariate general linear model]   NS     follicular cycle phase: 274.8 \u00b1 87.3; luteal cycle phase: 296.8 \u00b1 82.9   follicular cycle phase: 264.0 \u00b1 87.4; luteal cycle phase: 264.4 \u00b1 83.0     1.9. IGF\u20102 (insulin\u2010like growth factor\u20102)   29   15   mean \u00b1 SEM, ng/ml   406.2 \u00b1 27.5 (rASRM I\u2010II); 430.6\u00b130.2 (rASRM III\u2010IV)   442.6 \u00b1 30.5   NS   I\u2010IV   follicular/ luteal   Gurgan 1999      1.10.a. IGFBP\u20103 (insulin\u2010like growth factor binding protein\u20103)   29   15   mean \u00b1 SEM, ng/ml   1256.2 \u00b1 31 (rASRM I\u2010II); 1210.7 \u00b1 51.9 (rASRM III\u2010IV)   1250.6 \u00b1 33.4   NS   I\u2010IV   follicular/ luteal   Gurgan 1999      1.10.b. IGFBP\u20103 (insulin\u2010like growth factor binding protein\u20103)   36   36   mean \u00b1 SD, ng/ml   crude values   NS   I\u2010IV   luteal   Philippoussis 2004      48.2 \u00b1 8.8   46.8 \u00b1 7.9     adjusted values (indication for surgery, BMI, and presence of uterine leiomyoma using a univariate general linear model]    NS     48.2 \u00b1 7.8   45.7 \u00b1 7.9     1.11.a. leptin   60   20   median (IQR), ng/ml   4.3 (5.1)   5.2 (11.2)   NS   I\u2010IV   n/a   Ozhan 2014      1.11.b. leptin   69   32   median (IQR), pg/ml   1.48 (0.1 \u2010 16.7)   1.03 (0.3 \u2010 67.3)   0.95   I\u2010IV   n/a   Paiva 2014      1.11.c. leptin   42   25   mean \u00b1 SEM, ng/ml   12.5 \u00b1 8.4 (rASRM I\u2010II); 11.8 \u00b1 7.7 (rASRM III\u2010IV)   12.5 \u00b1 9.4   NS   I\u2010IV   any   Vigano 2002      1.11.d. leptin   33   30   mean \u00b1 SD, \u03bcg/L   3.145 \u00b1 0.389   2.088 \u00b1 0.373 (tubal factor infertility) 1.963 \u00b1 0.410 (benign ovarian cyst)   NS   I\u2010IV   any   Wei 2005      1.12. PDGF (platelet derived growth factor)   17   23   median (IQR), pg/ml   98.7 (82.7 \u2010 149.5)   99.7 (80.1 \u2010 145.6)   0.682   I\u2010II   luteal   Kalu 2007      1.13.a. VEGF (vascular endothelial growth factor)   46   24   mean \u00b1 SEM, pg/ml   240.92 \u00b1 19.77   222.37 \u00b1 26.72   NS   I\u2010IV   follicular/ luteal   Cho 2007      1.13.b. VEGF (vascular endothelial growth factor)   10   7   median (IQR), pg/ml   0.135 (0.109 \u2010 0.624)   0.107 (0.097 \u2010 0.124)   0.093   II\u2010IV   follicular   Da Silva 2014      1.13.c. VEGF (vascular endothelial growth factor)   131   146   mean \u00b1 SD, pg/ml   crude values   NS   I\u2010IV   luteal   Gagne 2003b      241 \u00b1 164   221 \u00b1 128     adjusted (indication for surgery, infertility, BMI, gravidity, pelvic pain and length of menses, using a univariate general linear model]    NS     230 \u00b1 149   222 \u00b1 149     1.13.d. VEGF (vascular endothelial growth factor)   90   89   mean \u00b1 SEM, ng/l   46.7 \u00b1 10   53.3 \u00b1 9.3   NS   n/a   follicular/ luteal   Kianpour 2013      1.13.e. VEGF\u2013A (vascular endothelial growth factor A)   40   20   mRNA, relative quantification   1.04 (0.6 \u2010 1.9) DIE; 1.12 (0.5 \u2010 1.9) endometrioma   1 (0.1 \u2010 1.9)   0.581   n/a   follicular   Mabrouk 2012      1.13.f. VEGF (vascular endothelial growth factor)   68   70   median (IQR), pg/ml   26.32 (3.18 \u2010 63.36)   31.80 (7.28 \u2010 79.35)   0.22   I\u2010IV   follicular/ luteal   Othman 2008      1.13.g. VEGF (vascular endothelial growth factor)   69   32   median (IQR), pg/ml   6.0 (0.0 \u2010 37.0 )   7.2 (0.0 \u2010 35.7)   0.25   I\u2010IV   n/a   Paiva 2014      2. Apoptosis markers       2.1. annexin V   69   32   median (IQR), ng/ml   3.59 (2.50 \u2010 13.6)   3.69 (2.6 \u2010 5.0)   0.46   I\u2010IV   n/a   Paiva 2014      2.2. apoptotic cells   32   30   mean \u00b1 SD, %   6.34 \u00b1 1.94   5.68 \u00b1 2.14   NS   I\u2010II   peri ovulatory   Mier\u2010Cabrera 2011      2.3. sFas (soluble Fas)   17   23   median (IQR), pg/ml   450.0 (345.9 \u2010 723.1)   484.6 (366.4 \u2010 557.2)   0.827   I\u2010II   luteal   Kalu 2007      2.4. anti\u2010survivin Abs (anti\u2010survivin antibodies)   98   47   median, OD   0.078   0.119   NS   I\u2010IV   n/a   Lamp 2012      3. Cell adhesion molecules and other matrix\u2010related proteins       3.1. biglycan   56   40   mean \u00b1 SD, ng/ml   13.8 \u00b1 7.0   14.5 \u00b1 11.8 (benign ovarian cyst); 12.9 \u00b1 9.1 (healthy women)   0.7487   I\u2010IV   follicular/ luteal   Kocbek 2014b      3.2.a. sICAM\u20101 (soluble form of intercellular adhesion molecule\u20101)   15   15   mean \u00b1 SD, OD   0.43 \u00b1 0.1   0.44 \u00b1 0.1   NS   I\u2010IV   follicular/ luteal   De Placido 1998      3.2.b. sICAM\u20101 (soluble form of intercellular adhesion molecule\u20101)   11   9   mean, ng/ml   8.31   10.3   NS   I\u2010II   luteal   Goluda 1998      3.2.c. sICAM\u20101 (soluble form of intercellular adhesion molecule\u20101)   69   32   median (IQR), pg/ml   181.8 (115.3 \u2010 338.3)   176.0 (120.2 \u2010 337.8)   0.6   I\u2010IV   n/a   Paiva 2014      3.2.d. sICAM\u20101 (soluble form of intercellular adhesion molecule\u20101)   71   49   mean \u00b1 SD, ng/ml   257.7 \u00b1 72.9   240.7 \u00b1 70.7   0.21   I\u2010IV   n/a   Somigliana 2002      3.3. sE\u2010selectin (soluble E selectin)   11   9   mean, ng/ml   1.21   1.39   NS   I\u2010II   luteal   Goluda 1998      3.4. MMP\u20109 (matrix metalloproteinase\u20109)   40   20   mRNA, relative quantification   0.76 (0.1 \u2010 5.6) DIE; 1.14 (0.1 \u2010 5.6) endometrioma   1 (0.1 \u2010 1.9)   0.676   n/a   follicular   Mabrouk 2012      4. Cytoskeleton molecules       4.1. CK 19 (cytokeratin\u201019)   44   32   mean \u00b1 SD, ng/ml   1.1 \u00b1 1.1   1.0 \u00b1 1.3   0.77   n/a   follicular/ luteal   Kuessel 2014      5. DNA\u2010repair/telomere maintenance molecules       5.1. TL (telomere length)   25   25   ANOVA   (F(1,33) = 284 642]   0.36   I\u2010IV   luteal   Hapangama 2008      6. Hormonal markers       6.1. E2 (oestradiol)   25   25   mean, pg/l   window of implantation: 423; late luteal cycle phase: 217   window of implantation: 393; late luteal cycle phase: 341   NS   I\u2010IV   luteal   Hapangama 2008      6.2. FSH (follicle stimulating hormone)   28   21   mean \u00b1 SD, IU/ml   3.5 \u00b1 0.3 \u2010 4.5 \u00b10.4   4.1 \u00b1 0.4   NS   I\u2010IV   luteal   Lima 2006      6.3. LH (luteinizing hormone)   28   21   mean \u00b1 SD, IU/ml   2.7 \u00b1 0.3 \u2010 3.9 \u00b1 0.3   2.9 \u00b1 0.3   NS   I\u2010IV   luteal   Lima 2006      6.4. progesterone   25   25   mean, ng/ml   window of implantation: 8.61; late luteal cycle phase: 2.54   window of implantation: 7.38; late luteal cycle phase: 4.20   NS   I\u2010IV   luteal   Hapangama 2008      7. Immune system and inflammatory markers       7.1. Autoantibodies      7.1.1.a. anti\u2010endometrial Abs, MW 28 kd (anti\u2010endometrial auto antibodies with molecular weight of 28 kilodalton    18   18   n (%)   6 (33.3%)   5 (27.8%)   NS   I\u2010IV   n/a   Gorai 1993      7.1.1.b. anti\u2010endometrial Abs, MW 38 kd (anti\u2010endometrial auto antibodies with molecular weight of 38 kilodalton    18   18   n (%)   5 (27.8%)   1 ( 5.6%)   NS   I\u2010IV   n/a   Gorai 1993      7.1.1.c. anti\u2010endometrial Abs, MW 64 kd (anti\u2010endometrial auto antibodies with molecular weight of 64 kilodalton    18   18   n (%)   7 (38.9%)   4 (22.2%)   NS   I\u2010IV   n/a   Gorai 1993      7.1.1.d. AEA (anti\u2010endometrial auto antibodies)   60   20   median (IQR), OD   0.033 (0.046)   0.036 (0.041)   NS   I\u2010IV   n/a   Ozhan 2014      7.1.2. anti\u2010sperm Abs (anti\u2010sperm auto antibodies)   50   48   median \u00b1 mean deviation, fg/sperm   6.43 \u00b1 6.98 (infertile participants); 10.16 \u00b1 7.24 (fertile participants)   8.57 \u00b1 17.05 (infertile participants); 8.56 \u00b1 8.38 (fertile participants)   NS   I   luteal   Szczepanska 2001a      7.1.3. anti\u2010ZP Abs (anti\u2010zona pellucida auto antibodies)   50   48   median \u00b1 mean deviation, ng/oocyte   3.65 \u00b1 5.20 (infertile participants); 4.08 \u00b1 5.70 (fertile participants)   3.60 \u00b1 10.44 (infertile participants); 3.98 \u00b1 9.00 (fertile participants)   NS   I   luteal   Szczepanska 2001a      7.2. Chemokines      7.2.1.a. MCP\u20101 (monocyte chemotactic protein\u20101)   33   17   mean \u00b1 SD, pg/ml   97.34 \u00b1 107.36   79.14 \u00b1 53.43   0.76   I\u2010IV   follicular   Drosdzol\u2010Cop 2012b      7.2.1.b. MCP\u20101 (monocyte chemotactic protein\u20101)   94   76   mean \u00b1 SE, pg/ml   321.0 \u00b1 14.7   348.6 \u00b1 21.4   NS   I\u2010IV   follicular   Kim 2008      7.2.1.c. MCP\u20101 (monocyte chemotactic protein\u20101)   69   32   median (IQR), pg/ml   25.2 (14.2 \u2010 73.9)   27.5 (14.9 \u2010 65.9)   0.27   I\u2010IV   n/a   Paiva 2014      7.2.1.d. MCP\u20101 (monocyte chemotactic protein\u20101)1    63   78   range, pg/ml   25 \u2010 320;   10 \u2010 350   NS   II\u2010IV   follicular/ luteal/unknown   Seeber 2008      AUC (CIs) 0.597 (0.503 \u2010 0.691)     7.3. other Cytokines      7.3.1. Epo (erythropoietin)   33   22   mean \u00b1 SD, IU/ml   60.22 \u00b1 9.11   30.32 \u00b1 7.94   0.099   I\u2010IV   n/a   Yagmur 2013      7.3.2.a. sGM\u2010CSF (soluble granulocyte macrophage\u2010colony stimulating factor)   28   20   %OD increase over background \u00b1 S.E.M   2.63 \u00b1 0.25   2.75 \u00b1 0.19   NS   I\u2010IV   n/a   Matalliotakis 2003a      7.3.2.b. GM\u2010CSF (granulocyte macrophage\u2010colony stimulating factor)   68   70   median (IQR), pg/ml   20.51 (14.5 \u2010 29.68)   11.97 (8.8 \u2010 20.19)   0.51   I\u2010IV   follicular/ luteal   Othman 2008      7.3.2.c. GM\u2010CSF (granulocyte macrophage\u2010colony stimulating factor)   69   32   median (IQR), pg/ml   0.58 (0.25 \u2010 3.02)   0.59 (0.3 \u2010 3.6)   0.84   I\u2010IV   n/a   Paiva 2014      7.3.3.a. IFN\u2010\u03b3 (interferon\u2010gamma)   60: 42 \u2010 rASRM I\u2010II; 18 \u2010 rASRM III\u2010IV)   37   mean rank values   47.98 (rASRM I\u2010II); 50.75 (rASRM III\u2010IV)   49.31   0.13   I\u2010IV   follicular   Hassa 2009      7.3.3.b. sIFN\u2010\u03b3 (soluble interferon\u2010gamma)   28   20   %OD increase over background \u00b1 S.E.M   1.1 \u00b1 0.13   1.0 \u00b1 0.12   NS   I\u2010IV   n/a   Matalliotakis 2003a      7.3.3.c. IFN\u2010\u03b3 (interferon\u2010gamma)   65   33   median (range), pg/ml   1.6 (0 \u2010 11.7)   2.1 (0 \u2010 6.6)   0.571   I\u2010IV   follicular/ luteal   Podgaec 2007      7.3.3.d. IFN\u2010\u03b3 (interferon\u2010gamma)   63   78    below detection limit of assay   below detection limit of assay    II\u2010IV   follicular/ luteal/unknown   Seeber 2008      7.3.3.e. INF\u2010\u03b3 (interferon\u2010gamma)   36   35   mean \u00b1 SD, pg/ml   1.91 \u00b1 0.18   2.05 \u00b1 0.24   0.07   I\u2010IV   n/a   Wu 1998      7.3.4.a. MIF (macrophage migration inhibitory factor)   60   20   median (IQR), pg/ml   901.5 (556.1)   585.0 (434.0)   NS   I\u2010IV   n/a   Ozhan 2014      7.3.4.b. MIF (macrophage migration inhibitory factor)   69   32   median (IQR), pg/ml   544 (237 \u2010 2354)   583 (196 \u2010 3791)   0.51   I\u2010IV   n/a   Paiva 2014      7.3.4.c. MIF (macrophage migration inhibitory factor)1    63   78   range, ng/ml   5 \u2010 100   3 \u2010 100   NS   II\u2010IV   follicular/ luteal/unknown   Seeber 2008      AUC (CIs) 0.539 (.443 \u2010 .634)     7.3.5.a. TNF\u2010\u03b1 (tumour necrosis factor alpha)   10   7   median (IQR), pg/ml   1765,2 (425,6 \u2010 2583,8)   221,3 (0,00 \u2010 1910,58)   0.243   II\u2010IV   follicular   Da Silva 2014      7.3.5.b. TNF\u2010\u03b1 (tumour necrosis factor alpha)   33   17   mean \u00b1 SD, pg/ml   7.40 \u00b1 12.55   4.87 \u00b1 1.56   0.26   I\u2010IV   follicular   Drosdzol\u2010Cop 2012a      7.3.5.c. TNF\u2010\u03b1 (tumour necrosis factor alpha)   15   20   median (IQR), pg/ml   4.00 (4.0 \u2010 4.0)   4.00 (4.0 \u2010 4.5)   0.638   I\u2010II   luteal   Kalu 2007      7.3.5.d. TNF\u2010\u03b1 (tumour necrosis factor alpha)   68   70   median (IQR), pg/ml   1.04 (0.84 \u2010 1.36)   1.07 (0.89 \u2010 1.47)   0.6   I\u2010IV   follicular/ luteal   Othman 2008      7.3.5.e. TNF\u2010\u03b1 (tumour necrosis factor alpha)   65   33   median (range), pg/ml   2.3 (0 \u2010 9.6)   3.7 (0 \u2010 10.4)   0.188   I\u2010IV   follicular/ luteal   Podgaec 2007      7.3.5.f. TNF\u2010\u03b1 (tumour necrosis factor alpha)   63   78   mean (range), pg/ml   0 \u2010 125   0 (0 \u2010 125)   NS   II\u2010IV   follicular/ luteal/unknown   Seeber 2008      AUC (CIs) 0.549 (0.453\u20130.645)     7.3.5.g. TNF\u2010\u03b1 (tumour necrosis factor alpha)   46   48   mean \u00b1 SD, pg/ml   23.2 \u00b1 43.6   17.0 \u00b1 27.1   NS   I\u2010IV   n/a   Vercellini 1993      7.3.5.h. TNF\u2010\u03b1 (tumour necrosis factor alpha)   33   22   mean \u00b1 SD, pg/ml   26.26 \u00b1 9.31   65.40 \u00b1 9.86   0.051   I\u2010IV   n/a   Yagmur 2013      7.4. Immune cells      7.4.1.Peripheral blood mononuclear cells (PBMC)      7.4.1.1.a. activated lymphocytes   60: 42 \u2010 rASRM I\u2010II; 18 \u2010 rASRM III\u2010IV)   37   mean rank values   49.31 (rASRM I\u2010II); 47.94 (rASRM III\u2010IV)   47.76   0.93   I\u2010IV   follicular   Hassa 2009      7.4.1.1.b. lymphocytes   22   20   mean \u00b1 SD, x10^3 cells/ml   1.63 \u00b1 0.44   1.7 \u00b1 0.3   NS   I\u2010IV   follicular   Gogacz 2014      7.4.1.1.c. lymphocytes   62   57   mean \u00b1 SD, 10^9/l   1.869 \u00b1 0.5   2.090 \u00b1 0.5   NS   I\u2010II   follicular/ luteal   Matveeva 1990      7.4.1.1.d. lymphocytes   61: 33 (endometrioma); 28 (non\u2010endometrioma)   33   mean \u00b1 SD, 10^3/\u00b5l   2.12 \u00b1 0.87 (endometrioma); 2.02 \u00b1 0.68 (non\u2010endometrioma)   2.25 \u00b1 0.66   0.463   III\u2010IV   n/a   Yavuzcan 2013      7.4.1.2.a. B\u2010lymphocytes, CD3\u2010/CD19+   19   26   mean \u00b1 SD, % of CD45+ cells   10.1 \u00b1 7.9   7.3 \u00b1 5.1   NS   I\u2010IV   follicular   Iwasaki 1993      7.4.1.2.b. B\u2010lymphocytes, CD19+   28   26   mean \u00b1 SD, %   11.6 \u00b1 3.2 (rASRM I\u2010II); 9.8 \u00b1 4.1 (rASRM III\u2010IV)   8.4 \u00b1 3.6   NS   I\u2010IV   follicular   Maeda 2002a      7.4.1.2.c. B\u2010lymphocytes, CD19+   56   68   mean \u00b1 SD, % among Lymphocytes   11.6 \u00b1 4.8   10.5 \u00b1 4.3   NS   I\u2010IV   n/a   Zhang 2006a      7.4.1.3. monocytes/ macrophages, CD14+   28   26   mean \u00b1 SD, %   17.9 \u00b1 10.2 (rASRM I\u2010II); 17.1 \u00b1 8.6 (rASRM III\u2010IV)   16.6 \u00b1 10.3   NS   I\u2010IV   follicular   Maeda 2002a      7.4.1.4. neutrophils   61: 33 (endometrioma); 28 (non\u2010endometrioma)   33   mean \u00b1 SD, 10^3/\u00b5l   4.14 \u00b1 1.73 (endometrioma); 4.68 \u00b1 2.18 (non\u2010endometrioma)   4.50 \u00b1 1.57   0.501   III\u2010IV   n/a   Yavuzcan 2013      7.4.1.5. NLR (neutrophil/ lymphocyte ratio)   61: 33 (endometrioma); 28 (non\u2010endometrioma)   33   mean \u00b1 SD   2.40 \u00b1 2.04 (endometrioma); 2.51 \u00b1 1.37 (non\u2010endometrioma)   2.11 \u00b1 0.86   0.555   III\u2010IV   n/a   Yavuzcan 2013      7.4.1.6.a. NK (natural killer cells)   60: 42 \u2010 rASRM I\u2010II; 18 \u2010 rASRM III\u2010IV)   37   mean rank values   41.36 (rASRM I\u2010II); 50.75 (rASRM III\u2010IV)   45.98   0.67   I\u2010IV   follicular   Hassa 2009      7.4.1.6.b. NK (natural killer cells), CD3\u2010/CD16+ or CD56+   19   26   mean \u00b1 SD, % of CD45+ cells   18.6 \u00b1 8.9   23.3 \u00b1 9.6   NS   I\u2010IV   follicular   Iwasaki 1993      7.4.1.6.c. NK (natural killer cells), CD16   28   26   mean \u00b1 SD, %   28.8 \u00b1 13.2 (rASRM I\u2010II); 24.9 \u00b1 11.5 (rASRM III\u2010IV)   26.9 \u00b1 11.2   NS   I\u2010IV   follicular   Maeda 2002a      7.4.1.6.d. NK (natural killer cells), CD56+   56   68   mean \u00b1 SD, % among lymphocytes   15.1 \u00b1 9.2   13.6 \u00b1 6.1   NS   I\u2010IV   n/a   Zhang 2006a      7.4.1.7.a. NKR CD158b+ (KIR2DL2+NK] (killer cell inhibitory receptor subfamily 2DL2 on NK cells)    42   40   mean \u00b1 SD, %   32.2 \u00b1 16.8   33.9 \u00b1 14.3   NS   I\u2010IV   n/a   Maeda 2002b      7.4.1.7.b. NKR CD158b+ (killer immunoglobulin\u2010like receptor on natural killer cells)   56   68   mean \u00b1 SD, % among CD56+ NK cells   38.1 \u00b1 14.5   36.0 \u00b1 13.9   NS   I\u2010IV   n/a   Zhang 2006a      7.4.1.8.a. NKR CD94+ (lectin\u2010like receptor on natural killer cells)   42   40   mean \u00b1 SD, %   52.6 \u00b1 17.9   56.2 \u00b1 15.7   NS   I\u2010IV   n/a   Maeda 2002b      7.4.1.8.b. NKR CD94+ (lectin\u2010like receptor on natural killer cells)   56   68   mean \u00b1 SD, % among CD56+ NK cells   54.5 \u00b1 14.9   50.0 \u00b1 16.9   NS   I\u2010IV   n/a   Zhang 2006a      7.4.1.9.a. T\u2010lymphocytes, CD3+/CD19\u2010   19   26   mean \u00b1 SD, % of CD45+ cells   68.3 \u00b1 10.6   66.4 \u00b1 10   NS   I\u2010IV   follicular   Iwasaki 1993      7.4.1.9.b. T\u2010lymphocytes, non MHC restricted, CD3+/CD16+ or CD56+   19   26   mean \u00b1 SD, % of CD45+ cells   4.5 \u00b1 3.0   6.6 \u00b1 5.6   NS   I\u2010IV   follicular   Iwasaki 1993      7.4.1.9.c. T\u2010lymphocytes, CD3+   28   26   mean \u00b1 SD, %   49.4 \u00b1 15.0 (rASRM I\u2010II); 47.3 \u00b1 15.9 (rASRM III\u2010IV)   52.5 \u00b1 11.2   NS   I\u2010IV   follicular   Maeda 2002a      7.4.1.9.d. T\u2010lymphocytes, CD3+   62   57   mean \u00b1 SD, %   60.1 \u00b1 8.4   60.4 \u00b1 6.6   NS   I\u2010II   follicular/ luteal   Matveeva 1990      7.4.1.9.e. T\u2010lymphocytes, CD2+   62   57   mean \u00b1 SD, %   67.4 \u00b1 9.0   68.2 \u00b1 8.3   NS   I\u2010II   follicular/ luteal   Matveeva 1990      7.4.1.9.f. T\u2010lymphocytes, CD3+   56   68   mean \u00b1 SD, % among lymphocytes   61.8 \u00b1 13.4   64.0 \u00b1 11.0   NS   I\u2010IV   n/a   Zhang 2006a      7.4.1.10. T\u2010lymphocytes (inducer\u2010T cells), CD4+/Leu 8+   19   26   mean \u00b1 SD, % of CD45+ cells   31.5 \u00b1 11.1   28.3 \u00b1 9.4   NS   I\u2010IV   follicular   Iwasaki 1993      7.4.1.11.a. T\u2010lymphocytes (T\u2010helper cells)   60: 42 \u2010 rASRM I\u2010II; 18 \u2010 rASRM III\u2010IV)   37   mean rank values   46.76 (rASRM I\u2010II); 46.33 (rASRM III\u2010IV)   50.07   0.76   I\u2010IV   follicular   Hassa 2009      7.4.1.11.b. T\u2010lymphocytes (T\u2010helper cells), CD4+/Leu 8\u2010   19   26   mean \u00b1 SD, % of CD45+ cells   10.0 \u00b1 4.1   10.2 \u00b1 5.9   NS   I\u2010IV   follicular   Iwasaki 1993      7.4.1.11.c. T\u2010lymphocytes (T\u2010helper cells), CD4+   28   26   mean \u00b1 SD, %   38.8 \u00b1 9.8 (rASRM I\u2010II);36.7 \u00b1 13.1 (rASRM III\u2010IV)   42.8 \u00b1 6.5   NS   I\u2010IV   follicular   Maeda 2002a      7.4.1.11.d. T\u2010lymphocytes, CD4+   62   57   mean \u00b1 SD, %   40.7 \u00b1 6.8   43.7 \u00b1 7.4   NS   I\u2010II   follicular/ luteal   Matveeva 1990      7.4.1.11.e. T\u2010lymphocytes producing IL\u20102, CD4+/IL\u20102   32   30   mean \u00b1 SD (median; minimum\u2013maximum), %   4.74 \u00b1 2.51 (4; 1\u201312)   5.28 \u00b1 2.24 (5; 1\u201310)   NS   I\u2010II   periovulatory   Mier\u2010Cabrera 2011      7.4.1.11.f. T\u2010lymphocytes, CD4+   56   68   mean \u00b1 SD, % among lymphocytes   36.3 \u00b1 10.5   36.3 \u00b1 6.0   NS   I\u2010IV   n/a   Zhang 2006a      7.4.1.12.a. T\u2010lymphocytes (cytotoxic T\u2010cells), CD8+   28   26   mean \u00b1 SD, %   33.2 \u00b1 6.8 (rASRM I\u2010II); 30.1 \u00b1 9.6 (rASRM III\u2010IV)   34.2 \u00b1 7.8   NS   I\u2010IV   follicular   Maeda 2002a      7.4.1.12.b. T\u2010lymphocytes (T\u2010supressor cells), CD8+   60: 42 \u2010 rASRM I\u2010II; 18 \u2010 rASRM III\u2010IV)   37   mean rank values   51.04 (rASRM I\u2010II); 47.53 (rASRM III\u2010IV)   49.46   0.62   I\u2010IV   follicular   Hassa 2009      7.4.1.12.c. T\u2010lymphocytes, CD8+   62   57   mean \u00b1 SD, %   21.9 \u00b1 5.6   23.7 \u00b1 6.8   NS   I\u2010II   follicular/ luteal   Matveeva 1990      7.4.1.12.d. T\u2010lymphocytes, CD8+   56   68   mean \u00b1 SD, % among lymphocytes   39.1 \u00b1 7.4   40.7 \u00b1 7.4   NS   I\u2010IV   n/a   Zhang 2006a      7.4.1.12.e. T\u2010lymphocytes producing IL\u20102, CD8+/IL\u20102   32   30   mean \u00b1 SD (median; minimum\u2013maximum), %   4.03 \u00b1 2.24 (4; 1\u20139)   4.68 \u00b1 2.1 (5; 1\u201311)   NS   I\u2010II   periovulatory   Mier\u2010Cabrera 2011      7.4.1.12.f. T\u2010lymphocytes producing interferon\u2010gamma, CD8+/IFN\u2010\u03b3   32   30   mean \u00b1 SD (median; minimum\u2013maximum), %   6.17 \u00b1 1.85 (6; 2\u201310)   6.59 \u00b1 1.69 (7; 3\u20139)   NS   I\u2010II   periovulatory   Mier\u2010Cabrera 2011      7.4.1.13.a. Tregs (regulatory T cells)   22   20   mean \u00b1 SD, %CD4+   6.5 \u00b1 3.2   6.5 \u00b1 3.7   NS   I\u2010IV   follicular   Gogacz 2014      7.4.1.13.b. Treg cells (regulatory T cells), CD25+ FOXP3+   17   15   median (IQR), %   4.4 (3.11 \u2010 5.5)   5.2 (4.1 \u2010 5.71)   0.4&   III\u2010IV   follicular   Olkowska\u2010Truchanowicz 20132      7.4.1.13.c. Treg cells (regulatory T cells), CD25low FOXP3+    17   15   median (IQR), %   3.3 (2.1 \u2010 4.9)   3.7 (2.4 \u2010 4.5)   0.95   III\u2010IV   follicular   Olkowska\u2010Truchanowicz 20132      7.4.1.14.a. WBC (white blood cells)   22   20   mean \u00b1 SD, x10^3 cells/ml   7.53 \u00b1 2.31   6.8 \u00b1 1.8   NS   I\u2010IV   follicular   Gogacz 2014      7.4.1.14.b. WBC (white blood cells)   50   36   mean \u00b1 SD, n/ul   7.299 \u00b1 1.622   6.743 \u00b1 1.632   0.118   I\u2010IV   n/a   Tuten 2014a      7.4.1.14.c. WBC (white blood cells)   61: 33 (endometrioma); 28 (non\u2010endometrioma)   33   mean \u00b1 SD, 10^3/\u00b5l   7081.5 \u00b1 2170.6 (endometrioma); 7268.9 \u00b1 2321.7 (non\u2010endometrioma)   7311.2 \u00b1 2027.2   0.902   III\u2010IV   n/a   Yavuzcan 2013      7.4.2. Other blood cells and blood cell parameters      7.4.2.1. Haemoglobin   61: 33 (endometrioma); 28 (non\u2010endometrioma)   33   mean \u00b1 SD, g/dl   11.9 \u00b1 1.6 (endometrioma); 12.0 \u00b1 1.4 (non\u2010endometrioma)   12.0 \u00b1 1.8   0.97   III\u2010IV   n/a   Yavuzcan 2013      7.4.2.2. MPV (mean platelet volume)   61: 33 (endometrioma); 28 (non\u2010endometrioma)   33   mean \u00b1 SD, fl   8.75 \u00b1 1.52 (endometrioma); 8.56 \u00b1 1.27 (non\u2010endometrioma)   8.56 \u00b1 1.27   0.836   III\u2010IV   n/a   Yavuzcan 2013      7.4.2.3. Platelet count   61: 33 (endometrioma); 28 (non\u2010endometrioma)   33   mean \u00b1 SD, 10^3/\u00b5l   269848 \u00b1 65202 (endometrioma); 298964 \u00b1 107813 (non\u2010endometrioma)   286484 \u00b1 67636   0.373   III\u2010IV   n/a   Yavuzcan 2013      7.4.2.4. PLR (Platelet/ Lymphocyte ratio)   61: 33 (endometrioma); 28 (non\u2010endometrioma)   33   mean \u00b1 SD   162.84 \u00b1 141.28 (endometrioma); 159.14 \u00b1 61.20 (non\u2010endometrioma)   132.45 \u00b1 35.74   0.358   III\u2010IV   n/a   Yavuzcan 2013      7.5. Interleukins      7.5.1.a. IL\u20101\u03b2   22   30   median (IQR), pg/ml   10.98 (8.65, 18.52)   9.7 (3.97, 15.46)   NS   I\u2010IV   follicular/ luteal   Bedaiwy 2002      7.5.1.b. IL\u20101\u03b2   15   20   median (IQR), pg/ml   5.0 (5.0 \u2010 5.0)   5.0 (5.0 \u2010 5.0)   0.625   I\u2010II   luteal   Kalu 2007      7.5.1.c. IL\u20101\u03b2   39   19   mean \u00b1 SE, pg/ml   0.12 \u00b1 0.09   0.17 \u00b1 0.11   NS   I\u2010IV   follicular   Oku 2004      7.5.1.d. IL\u20101\u03b2   58   27   median (IQR), pg/ml   0.00 (0.00 \u2010 0.33)   0.08 (0.00 \u2010 4.75)   0.054   I\u2010IV   follicular   Szubert 2014      7.5.2.a. IL\u20102   33   17   mean \u00b1 SD, pg/ml   124.19 \u00b1 336.39   247.65 \u00b1 486.15   0.86   I\u2010IV   follicular   Drosdzol\u2010Cop 2012b      7.5.2.b. IL\u20102   60: 42 \u2010 rASRM I\u2010II; 18 \u2010 rASRM III\u2010IV   37   mean rank values   47.88 (rASRM I\u2010II); 42.17 (rASRM III\u2010IV)   53.59   0.15   I\u2010IV   follicular   Hassa 2009      7.5.2.c. IL\u20102   30   20   mean, ng/L   3.6   3.6   NS   I\u2010IV   n/a   Li 2005      7.5.2.d. IL\u20102   68   70    below detection limit of assay   below detection limit of assay    I\u2010IV   follicular/ luteal   Othman 2008      7.5.2.e. IL\u20102   65   33   median (range), pg/ml   7.4 (0 \u2010 34.1)   8.3 (0 \u2010 26)   0.447   I\u2010IV   follicular/ luteal   Podgaec 2007      7.5.3.a. IL\u20104   60: 42 \u2010 rASRM I\u2010II; 18 \u2010 rASRM III\u2010IV)   37   mean rank values   47.76 (rASRM I\u2010II); 48.25 (rASRM III\u2010IV)   50.77   0.5   I\u2010IV   follicular   Hassa 2009      7.5.3.b. IL\u20104   65   33   median (range), pg/ml   1.9 (0 \u2010 6.3)   2.0 (0 \u2010 4.1)   0.731   I\u2010IV   follicular/ luteal   Podgaec 2007      7.5.4.a. IL\u20106   33   17   mean \u00b1 SD, pg/ml   23.59 \u00b1 44.17   12.63 \u00b1 15.75   0.16   I\u2010IV   follicular   Drosdzol\u2010Cop 2012a      7.5.4.b. IL\u20106   44   51   mean \u00b1 SEM, pg/ml   5.3 \u00b1 0.9   12.9 \u00b1 4.0   0.295   III\u2010IV   n/a   Jee 2008      7.5.4.c. IL\u20106   15   20   median (IQR), pg/ml   5.0 (5.0 \u2010 5.0)   5.0 (5.0 \u2010 5.0)   0.946   I\u2010II   luteal   Kalu 2007      7.5.4.d. IL\u20106   63   78   mean (range), pg/ml   0 \u2010 160   0 \u2010 160   NS   II\u2010IV   follicular/ luteal/unknown   Seeber 2008      AUC (CIs) 0.556 (0.454\u20130.650)     7.5.4.e. IL\u20106   45   35   median (IQR), pg/ml   0.6 (0 \u2010 1.4)   1.0 (0.4 \u2010 1.9)   0.09   I\u2010IV   any   Somigliana 2004      7.5.4.f. IL\u20106   41   26   mean, pg/ml   20   10   NS   III\u2010IV   n/a   Suen 2014      7.5.5.a. IL\u20108   47   22   mean \u00b1 SD, pg/ml   10.17 \u00b1 7.98   9.81 \u00b1 8.11   NS   I\u2010IV   follicular   Barcz 2002      7.5.5.b. IL\u20108   20   10   mean \u00b1 SD, ng/ml   0.1 \u00b1 0.096   0.08 \u00b1 0.04   0.396   III\u2010IV   follicular/ luteal   Calienno 2008      7.5.5.c. IL\u20108   25   22   median (IQR), ng/ml   2.5 (1.1 \u2010 4.1)   1.5 (1 \u2010 1.9)   0.27   I\u2010IV   follicular/ luteal   Gazvani 1998      7.5.5.d. IL\u20108   15   20   median (IQR), pg/ml   9.4 (5.4 \u2010 13.8)   5.7 (5.0 \u2010 8.4)   0.074   I\u2010II   luteal   Kalu 2007      7.5.5.e. IL\u20108   68   70    below detection limit of assay   below detection limit of assay    I\u2010IV   follicular/ luteal   Othman 2008      7.5.5.f. IL\u20108   60   20   median (IQR), ng/ml   150.1 (1650.9)   120.6(1049.8)   NS   I\u2010IV   n/a   Ozhan 2014      7.5.6.a. IL\u201010   40   40   mean \u00b1 SD, pg/ml   13.05 \u00b1 29.55   10.43 \u00b17.56   0.604   I\u2010II   follicular   Andreoli 2011      7.5.6.b. IL\u201010   20   10   mean \u00b1 SEM, pg/ml   9.2 \u00b1 7.0   8.6 \u00b1 5.0   NS   n/a   luteal   Braun 1996      7.5.6.c. IL\u201010   60: 42 \u2010 rASRM I\u2010II; 18 \u2010 rASRM III\u2010IV)   37   mean rank values   48.95 (rASRM I\u2010II); 53.56 (rASRM III\u2010IV)   46.84   3.43   I\u2010IV   follicular   Hassa 2009      7.5.6.d. IL\u201010   65   33   median (range), pg/ml   3.2 (0 \u2010 12.9)   3.1 (0 \u2010 7.5)   0.904   I\u2010IV   follicular/ luteal   Podgaec 2007      7.5.7.a. IL\u201012   40   40   mean \u00b1 SD, pg/ml   7.95 \u00b1 3.14   14.39 \u00b1 11.20   0.203   I\u2010II   follicular   Andreoli 2011      7.5.7.b. IL\u201012   22   32   median (IQR), pg/ml   0.00 (0.00, 0.00)   0.00 (0.00, 31.32)   NS   I\u2010IV   follicular/ luteal   Bedaiwy 2002      7.5.7.c. IL\u201012   72   33   mean \u00b1 SD, pg/ml   152.14 \u00b1 22.59   97.1 \u00b1 19.00   NS   I\u2010IV   follicular/ luteal   Fairbanks 2009      7.5.7.d. IL\u201012   61   12   mean \u00b1 SD, pg/ml   80.1 \u00b1 49.6 (pelvic endometriosis); 76.5 \u00b1 32.1 (endometrioma)   69.6 \u00b1 35.4   0.74   I\u2010IV   follicular   Kubatova 2013      7.5.7.e. IL\u201012   41   26    below detection limit of assay   below detection limit of assay    III\u2010IV   n/a   Suen 2014      7.5.7.f. IL\u201012   53   11   median (range), pg.ml   120 (86.5 \u2010 355) (rASRM I\u2010II); 110 (20 \u2010 460) (rASRM III\u2010IV)   175 (45 \u2010 380)   NS   I\u2010IV   luteal   Szczepanska 2001b      7.5.8. IL\u201013   21   32   median (IQR), pg/ml   44.57 (44.57, 49.87)   44.57 (44.57, 44.57)   NS   I\u2010IV   follicular/ luteal   Bedaiwy 2002      7.5.9. IL\u201015   68   70    below detection limit of assay   below detection limit of assay    I\u2010IV   follicular/ luteal   Othman 2008      7.5.10.a. IL\u201016   22   22   median (IQR), pg/ml   539.4   778.1   NS   I\u2010IV   n/a   Lin 2005      7.5.10.b. IL\u201016   22   22   median (range), pg/ml   290.5 (89.4 \u2010 2181.2   296.8 (88.3 \u2010 1513.6)   NS   I\u2010IV   follicular/ luteal   Zhang 2005a      7.5.11.a. IL\u201017   40   40   mean \u00b1 SD, pg/ml   4.83 \u00b1 8.60   2.35 \u00b1 2.40   0.325   I\u2010II   follicular   Andreoli 2011      7.5.11.b. IL\u201017   69   32    below detection limit of assay   below detection limit of assay    I\u2010IV   n/a   Paiva 2014      7.5.12.a. IL\u201018   72   33   mean \u00b1 SD, pg/ml   70.52 \u00b1 11.53   62.07 \u00b1 8.08   NS   I\u2010IV   follicular/ luteal   Fairbanks 2009      7.5.12.b. IL\u201018   56   22   mean \u00b1 SD, pg/ml   391.07 \u00b1 119.71   373.42 \u00b1 129.11   NS   I\u2010II   follicular   Glitz 2009      7.5.12.c. IL\u201018   39   19   mean \u00b1 SE, pg/ml   177.17 \u00b1 28.37   174.14 \u00b1 27.48   0.945   I\u2010IV   follicular   Oku 20043      7.5.12.d. IL\u201018   39   21   mean \u00b1 SD, pg/ml   8 1. 86 \u00b1 18. 22   78. 99 \u00b1 28. 58   NS   I\u2010IV   n/a   Zhang 2005b      7.5.13. IL\u201023   40   40   mean \u00b1 SD, pg/ml   6.49 \u00b1 4.71   10.12 \u00b1 9.87   0.209   I\u2010II   follicular   Andreoli 2011      7.6. Other immune/ inflammatory markers      7.6.1. C3a (anaphylatoxin)   109   51   median (range) ng/ml   102 (27 \u2010 2213)   105 (32 \u2010 2340)   0.84   I\u2010IV   any   Fassbender 2009      7.6.2. sCD23 (soluble CD23, low\u2010affinity IgE receptor)   44   58   mean \u00b1 SD, U/ml   menstrual cycle phase: 42.85 \u00b1 3.93 late follicular cycle phase: 52.98 \u00b1 10.58   menstrual cycle phase: 54.47 \u00b1 7.21late follicular cycle phase: 58.08 \u00b1 8.09   0.132 0.697   I\u2010IV   menstrual and follicular   Ramos 2012      7.6.3. sCD163 (soluble haemoglobin scavenger receptor)   44   51   mean \u00b1 SEM, ng/ml   3431.7 \u00b1 343.9   3,231.0 \u00b1 391.7   0.212   III\u2010IV   n/a   Jee 2008      7.6.4.a. CRP (C\u2010reactive protein)   50   50   mean (range)   3.57 (0.3 \u2010 27.66)   1.79 (0.21 \u2010 10.85)   0.101   I\u2010IV   early follicular   Dayangan Sayan 2013      7.6.4.b. CRP (C\u2010reactive protein)   90   89   mean \u00b1 SEM, \u00b5g/ml   7.6 \u00b1 1.7   6.9 \u00b1 2.1   NS   n/a   follicular/ luteal   Kianpour 2012      7.6.4.c. CRP (C\u2010reactive protein)   70   32   median (IQR), mg/l   1.90 (1.50 \u2010 2.70)   2.00 (1.60 \u2010 2.80)   0.556   I\u2010IV   follicular   Szubert 2014      7.6.4.d. hs\u2010CRP (high sensitive C\u2010reactive protein)   370   464   median (range), ng.ml   0.82 (0.04 \u2010 42.89]   0.9 (0.03 \u2010 43.73]   0.599   I\u2010IV   follicular/ luteal/unknown   Thubert 2014      7.6.4.e. CRP (C\u2010reactive protein)   50   36   mean \u00b1 SD, mg/ml   3.7 \u00b1 4.4   2.3 \u00b1 2.2   0.062   I\u2010IV   n/a   Tuten 2014a      7.6.4.f. CRP (C\u2010reactive protein)   18   14   median (95% CI), mg/l   1 (1 \u2010 2)   2 (1 \u2010 3)   0.18   I\u2010IV   follicular/ luteal   Riley 2007      7.6.5. sHLA\u2010I (soluble human leukocyte class I antigens)   15   15   mean \u00b1 SD, OD   0.55 \u00b1 0.3   0.35 \u00b1 0.1   0.06   I\u2010IV   follicular/ luteal   De Placido 1998      7.6.6. Immunoglobulins IgG   62   57   mean \u00b1 SD, mg%   1260.3 \u00b1 378.7   1170.9 \u00b1 342.4   NS   I\u2010II   follicular/ luteal   Matveeva 1990      7.6.7. ImmunoglobulinsIgA   62   57   mean \u00b1 SD, mg%   196.6 \u00b1 71.2   181.0 \u00b1 78.3   NS   I\u2010II   follicular/ luteal   Matveeva 1990      7.6.8. MPO (myeloperoxidase)   10   7   median (IQR), OD   0,168 (0,139 \u2010 0,491)   0,211 (0,164 \u2010 0,351)   0.757   II\u2010IV   follicular   Da Silva 2014      7.6.9. NAG (N\u2010acetyl\u2010b\u2010Dglucosaminidase)   10   7   median (IQR), OD   85,53 (43,52 \u2010 286,56)   57,66 (38,17 \u2010 101,15)   0.4079   II\u2010IV   follicular   Da Silva 2014      7.6.10. PGE2 (prostaglandin E2)   58   28   median (IQR), ng/ml   3.75 (3 \u2010 6.5)   4 (2 \u2010 7)   NS   I\u2010IV   any   Khan 2012      7.6.11. PLA2G2A (phospholipase A2 group IIA)   53   38   mean \u00b1 SD, ng/ml   2.9 \u00b1 2.1   3.1 \u00b1 2.2   0.7989   I\u2010IV   follicular/ luteal   Kocbek 2014a      7.6.12.a. RANTES (regulated on activation, normal T cell expressed and secreted)   17   23   median (IQR), pg/ml   789.4 (550.8 \u2010 1009.5)   662.5 (422.8 \u2010 960.4)   0.35   I\u2010II   luteal   Kalu 2007      7.6.12.b. RANTES (regulated on activation, normal T cell expressed and secreted)   23   9   range, pg/ml   5,200 \u2010 57,800   3,875 \u2010 35,100   NS   I\u2010IV   n/a   Markham 1997a      7.6.13. Phospholipid fatty acids   64   74   mean \u00b1 SD, %      I\u2010IV   follicular/ luteal   Khanaki 2012         14:0 (myristic acid)      0.29 \u00b1 0.21   0.26 \u00b1 0.11   0.24        16:0 (palmitic acid)      49.14 \u00b1 5.28   48.53 \u00b1 7.43   0.57        16:1(palmitoleic acid)      0.34 \u00b1 0.20   0.39 \u00b1 0.18   0.15        18:1 n\u20109 (oleic acid)      6.13 \u00b1 1.31   6.28 \u00b1 1.72   0.57        18:2 n\u20106 (linoleic acid)      20.31 \u00b1 3.19   19.66 \u00b1 3.59   0.26        18:3 n\u20103 (\u03b1\u2010linolenic acid)      0.37 \u00b1 0.19   0.35 \u00b1 0.14   0.44        20:4 n\u20106 (AA \u2010 arachidonic acid)      6.93 \u00b1 1.92   7.23 \u00b1 2.31   0.41        20:5 n\u20103 (eicosapentaenoic acid)      0.35 \u00b1 0.35   0.36 \u00b1 0.24   0.801        22:6 n\u20103 (docosahexaenoic acid)      0.79 \u00b1 0.82   0.70 \u00b1 0.75   0.5        SFA (saturated fatty acids)      61.89 \u00b1 4.57   62.14 \u00b1 6.32   0.78        MUFA (mono unsaturated fatty acids)      6.47 \u00b1 1.33   6.66 \u00b1 1.73   0.46        Omega\u20103 fatty acids      1.51 \u00b1 1.03   1.41 \u00b1 0.79   0.52        Omega\u20106 fatty acids      27.25 \u00b1 3.41   26.89 \u00b1 4.48   0.6        SFA/UFA (saturated fatty acids to unsaturated fatty acids)      1.80 \u00b1 0.33   1.84 \u00b1 0.39   0.45        Omega\u20103/Omega\u20106      0.05 \u00b1 0.03   0.05 \u00b1 0.02   0.57        EPA/AA (eicosapentaenoic acid to arachidonic acid)      0.05 \u00b1 0.05   0.05 \u00b1 0.04   0.74     8. Nerve growth markers       8.1. CNTF (ciliary neurotrophic factor)   69   32   median (IQR), pg/ml   897.7 (29.8 \u2010 2709.1)   450.5 930.5 \u2010 2999.7)   0.14   I\u2010IV   n/a   Paiva 2014      8.2. GDNF (glial\u2010derived neurotrophic factor)   69   32   median (IQR), pg/ml   58.2 (0 \u2010 168.1)   41.4 (0 \u2010 268.3)   0.43   I\u2010IV   n/a   Paiva 2014      8.1. CNTF (ciliary neurotrophic factor)   69   32   median (IQR), pg/ml   897.7 (29.8 \u2010 2709.1)   450.5 930.5 \u2010 2999.7)   0.14   I\u2010IV   n/a   Paiva 2014               Paiva 2014         9.1.a. DBP (vitamin D binding protein)   26   17   mean \u00b1 SE, \u00b5g/ml   449.4 \u00b1 24.4   424.5 \u00b1 23.5   0.4911   I\u2010IV   follicular   Borkowski 2008      9.1.b. DBP (vitamin D binding protein)   88   40   mean \u00b1 SEM, %Vo   0.568 \u00b1 0.034   0.563 \u00b1 0.047   NS   I\u2010IV   follicular/ luteal   Ferrero 2005a      9.2. enolase   60   20   median (IQR), ng/ml   6.9 (49.8)   4.0 (19.0)   NS   I\u2010IV   n/a   Ozhan 2014      9.3. PDPK1 (phosphoinositide dependent protein kinase 1)   60   20   median (IQR), OD   0.265 (0.053)   0.287 (0.075)   NS   I\u2010IV   n/a   Ozhan 2014      10. Oxidative stress markers       10.1. ascorbic acid   32   30   mean \u00b1 SD (median; minimum\u2013maximum), \u00b5mol/l   57.17 \u00b1 12.43 (122\u201324)   53.42 \u00b1 13.29 (106\u201328)   NS   I\u2010II   peri ovulatory   Mier\u2010Cabrera 2011      10.2. GSH (glutathione)   69   32   median (IQR), \u00b5g/ml   10517 (1494 \u2010 26945)   8741 (2267 \u2010 46420)   0.36   I\u2010IV   n/a   Paiva 2014      10.3. HSP70 (heat shock protein 70)   30   20   median (IQR), ng/ml   2.2 (1.5 \u2010 3)   2 (1 \u2010 3)   NS   I\u2010IV   any   Khan 2013      10.4. HSP70 (heat shock protein 70)   45   21   mean \u00b1 SD, ng/ml   1.240 \u00b1 1.279   0.875 \u00b1 1.336   0.634   I\u2010IV   n/a   Lambrinoudaki 2009      10.5. IMA (Ischemia\u2010modified albumin)   45   21   mean \u00b1 SD, U/ml   85.9 \u00b1 11.9   86.4 \u00b1 16.4   0.887   I\u2010IV   n/a   Lambrinoudaki 2009      10.6. malondialdehyde   32   30   mean \u00b1 SD (median; minimum\u2013maximum), \u00b5mol/l   27.17 \u00b1 8.67 (42\u201314)   23.75 \u00b1 6.46 (33\u20138)   NS   I\u2010II   peri ovulatory   Mier\u2010Cabrera 2011      10.7. nitrotyrosine   69   32    below detection limit of assay   below detection limit of assay    I\u2010IV   n/a   Paiva 2014      10.8. SOD3 (superoxide dismutase)   69   32   median (IQR), (x10^5), pg/ml   2.14 (0.96 \u2010 4.8)   2.03 (0.7 \u2010 7.1)   0.95   I\u2010IV   n/a   Paiva 2014      10.9. TRX (Thioredoxin)   45   21   mean \u00b1 SD, ng/ml   55.7 \u00b1 45.1   54.6 \u00b1 45.7   0.932   I\u2010IV   n/a   Lambrinoudaki 2009      10.10. vitamin E   69   32   median (IQR), \u00b5mol/ml   1.07 (0.04 \u2010 3.1)   0.98 (0.4 \u2010 2.4 0   0.82   I\u2010IV   n/a   Paiva 2014      11. Tumour markers       11.1. AFP (alpha\u2010fetoprotein)   36   36   mean \u00b1 SD, ng/ml   crude values   NS   I\u2010IV   luteal   Philippoussis 2004      1.9 \u00b1 0.9   1.8 \u00b1 1.5     adjusted values (indication for surgery, BMI, and presence of uterine leiomyoma using a univariate general linear model]    NS     1.9 \u00b1 1.3   1.8 \u00b1 1.3     11.2. CA\u201019.9 (cancer antigen\u201019.9)   45   35   median (IQR), IU/ml   9.8 (4.5\u201020.8)   7.4 (2.8\u201011.5)   0.11   I\u2010IV   any   Somigliana 2004      11.3.a. CA\u2010125 (cancer antigen\u2010125)   13   67   mean, U/ml   26.9   28.3   0.6389   I\u2010II   follicular   Barbosa 2009      11.3.b. CA\u2010125 (cancer antigen\u2010125)   18   14   median (95% CI), kU/l   25 (15 \u2010 46)   15 (11 \u2010 19)   0.06   I\u2010IV   follicular/ luteal   Riley 2007      11.4. c\u2010erbB\u20102 (HER\u20102/neu] (erythroblastosis oncogene B or human epidermal growth factor receptor\u20102 derived from glioblastoma)    36   36   mean \u00b1 SD, ng/ml   crude values   NS   I\u2010IV   luteal   Philippoussis 2004      2.8 \u00b1 1.7   2.6 \u00b1 1.3     adjusted values (indication for surgery, BMI, and presence of uterine leiomyoma using a univariate general linear model]    NS     2.7 \u00b1 1.6   2.9 \u00b1 1.6     11.5. HE4 (human epididymal secretory protein E4)   123   52   median, pM   43.5   41.2   NS   I\u2010IV   any   Hallamaa 2012      Notes: 1 The biomarker was assessed within a diagnostic model of combined biomarkers in this study.  2 The authors also report the negative findings for CD4+ and CD4+ CD25+ Treg cells, but these are not presented in the review as data were not shown Olkowska\u2010Truchanowicz 2013.  3 The authors also report the negative findings for IL\u20102, IL\u20104, IL\u20106, IL\u20108, IL\u201010, TNF\u2010a, GM\u2010CSF and IFN\u2010\u03b3, but these are not presented in the review as data were not shown Oku 2004.  For a comprehensive list of all biomarkers with their biological annotation, please see Appendix 1.         Footnotes",
        "Footnotes": "",
        "Appendix 8. Blood biomarkers of limited diagnostic value in endometriosis": "Biological group     Blood biomarker 1       1. Angiogenesis and growth markers   Glycodelin     IGFBP\u20103     Leptin     2. Cell adhesion molecules   sICAM\u20101     3. Immune system and inflammatory markers   Anti\u2010endometrial antibodies     hs\u2010CRP     sGM\u2010CSF     IL\u20101\u03b2     IL\u20102     IL\u20104     IL\u20106 (cut\u2010off > 1.9\u20102.0 pg/ml)     IL\u20108     IL\u201010     IL\u201012     IL\u201018     IFN\u2010\u03b3     Immune cells and cell parameters (lymphocytes and lymphocyte subsets, white blood cell, platelets, haemoglobin)      MCP\u20101     MIF     TNF\u2010\u03b1     4. Tumour markers   CA\u201019.9 (cut\u2010off > 37 U/ml)     CA\u2010125 (cut\u2010off > 10\u201014.7 U/ml; > 16\u201017.6 U/ml; > 20 U/ml; > 25\u201026 U/ml; > 30\u201033 U/ml; > 35\u201036 U/ml)      1 Limited diagnostic value was defined when at least 3 studies demonstrated low diagnostic estimates that do not meet or approach the criteria for either replacement or triage test and/or negative findings; we advise against further evaluation of these biomarkers in the diagnosis of endometriosis.  For a comprehensive list of all biomarkers with their biological annotation, please see Appendix 1.",
        "Appendix 9. Blood biomarkers that possibly have limited diagnostic value in endometriosis": "Biological group     Blood biomarker 1       1. Angiogenesis and growth factors   Angiogenic activity of serum     CAC     EGF     sEGF\u2010R     sFlt\u20101 (sVEGFR\u20101]     HGF     IGF\u20101     IGF\u20102     PDGF     2. Apoptosis markers   Annexin\u2010V     Anti\u2010Survivin Abs     Apoptotic cells     sFas     Survivin     3. Cell adhesion molecules   Biglycan     sE\u2010selectin     LN\u20101     MMP\u20109     4. Cytoskeleton molecules   CK 19     5. DNA\u2010repair/telomere maintenance molecules   Telomere length     6. Hormonal markers   Prolactin     7. Immune system and inflammatory markers   Anti\u2010laminin\u20101 auto Abs     Anti\u2010sperm and anti\u2010zona pellucida auto Abs     C3a     sCD23     CCR1     Copeptin     Epo     sHLA\u2010I     IL\u20106 (except for the cut\u2010off values reported in Table 4; Appendix 8)      IL\u201013     IL\u201015     IL\u201016     IL\u201017     IL\u201023     Immunoglobulins IgA and IgG     Immune cells and cell parameters (monocytes, macrophages, neutrophils, NLR, NKR CD158b+, NKR CD94+, Treg cells)      MPO     NAG     PGE2     Phospholipid fatty acids     PLA2G2A     RANTES     8. Nerve growth markers   CNTF     GDNF     NGF     NT4     9. Other peptides/proteins   DBP     Enolase     PDPK1     STX\u20105     10. Oxidative stress markers   Ascorbic acid     GSH     HSP70     IMA     Malondialdehyde     Nitrotyrosine     SOD3     Thiols     TRX     Vitamin E     11. Post\u2010transcriptional regulators of gene expression (microRNAs)   miR\u201017\u20105     miR\u2010122     miR\u2010199a     12. Tumour markers   AFP     CA\u201015.3     CA\u201019.9 (cut\u2010off > 37 U/ml)     CA\u201072 (TAG\u201072)     c\u2010erbB\u20102 (HER\u20102/neu)     HE4     13. Combined markers   All the reported combinations, excluding the tests presented in Table 4 as 'promising tests'      Notes: 1 Tests that appear to have limited diagnostic value, but there is insufficient data to confidently comment on their diagnostic role (less than 3 studies with low diagnostic estimates and/or negative findings); we advise considering further investigation with a focus of specific phases of menstrual cycle, specific types of endometriosis, by implementing different cut\u2010off values or by utilising different laboratory methods.  For a comprehensive list of all biomarkers with their biological annotation, please see Appendix 1."
    }
}